<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/252351-imidazo-1-2-a-pyridine-compounds-and-compositions by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 13:25:00 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 252351:IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND COMPOSITIONS</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND COMPOSITIONS</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>The present invention relates to novel imidazo[1,2- a]pyridine compounds of general formula (I) as well as pharmaceutically acceptable salts thereof; wherein R1, R2, R3 and R4 are as defined in the claims. The compounds have specific affinity for GABAA receptor and are therefore useful in the treatment and prevention of diseases modulated by &amp;#945;1- and &amp;#945;2-GABAA receptors.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>Technical field<br>
This invention is directed to agents with affinity for<br>
GABAA receptor, specifically to imidazo[1,2-a]pyridine<br>
compounds.<br>
Background of the invention<br>
GABAA receptor (γ-aminobutyric acidA) is a pentameric<br>
protein which forms a membrane ion channel. GABAA<br>
receptor is implicated in the regulation of sedation,<br>
anxiety, muscle tone, epileptogenic activity and memory<br>
functions. These actions are due to defined subunits of<br>
GABAA receptor, particularly the α1- and α2-subunits.<br>
Sedation is modulated by the α1-subunit. Zolpidem is<br>
characterized by a high affinity for the α1-receptors<br>
and its sedative and hypnotic action is mediated by<br>
these receptors in vivo. Similarly, the hypnotic action<br>
of zaleplon is also mediated by the α1-receptors.<br>
The anxiolytic action of diazepam is mediated by the<br>
enhancement of GABAergic transmission in a population<br>
of neurons expressing the α2-receptors. This indicates<br>
that the α2-receptors are highly specific targets for<br>
the treatment of anxiety.<br><br>
Muscle relaxation in diazepam is mainly mediated by α2-<br>
receptors, since these receptors exhibit a highly<br>
specific expression in spinal cord.<br>
The anticonvulsant effect of diazepam is partly due to<br>
α1-receptors. In diazepam, a memory-impairing compound,<br>
anterograde amnesia is mediated by α1-receptors.<br>
GABAA receptor and its α1- and α2-subunits have been<br>
widely reviewed by H. Mohler et al.(J. Pharmacol. Exp.<br>
Ther., 300, 2-8, 2002); H. Mohler et al.(Curr. Opin.<br>
Pharmacol., 1, 22-25, 2001); U. Rudolph et al.(Nature,<br>
401, 796-800, 1999); and D.J. Nutt et al. (Br. J.<br>
Psychiatry, 179, 390-396, 2001) .<br>
Diazepam and other classical benzodiazepines are<br>
extensively used as anxiolytic agents, hypnotic agents,<br>
anticonvulsants and muscle relaxants. Their side<br>
effects include anterograde amnesia, decrease in motor<br>
activity and potentiation of ethanol effects.<br>
In this context, the compounds of this invention are<br>
ligands of α1- and α2-GABAA receptor for their clinical<br>
application in sleep disorders, preferably insomnia,<br>
anxiety and epilepsy.<br>
Insomnia is a highly prevalent disease. Its chronicity<br>
affects 10% of the population and 30% when transitory<br>
insomnia is computed as well. Insomnia describes the<br>
trouble in falling asleep, staying asleep or waking up<br>
too early, experiencing a non-refreshing sleep, and is<br><br>
associated with next-day hangover effects such as<br>
weariness, lack of energy, low concentration and<br>
irritability. The social and health impact of this<br>
complaint is important and results in evident<br>
socioeconomic repercussions.<br>
Pharmacological therapy in the management of insomnia<br>
firstly included barbiturates and chloral hydrate, but<br>
these drugs elicit numerous known adverse effects, for<br>
example, overdose toxicity, metabolic induction, and<br>
enhanced dependence and tolerance. In addition, they<br>
affect the architecture of sleep by decreasing above<br>
all the duration and the number of REM sleep stages.<br>
Later, benzodiazepines meant an important therapeutic<br>
advance because of their lower toxicity, but they still<br>
showed serious problems of dependence, muscle<br>
relaxation, amnesia and rebound insomnia following<br>
discontinuation of medication.<br>
The latest known therapeutic approach has been the<br>
introduction of non-benzodiazepine hypnotics, such as<br>
pyrrolo [3, 4-b]pyrazines (zopiclone), imidazo[1,2-a]<br>
pyridines (Zolpidem) and, finally, pyrazolo[1,5-a]<br>
pyrimidines (zaleplon). Later, two new pyrazolo[1,5-a]<br>
pyrimidines, indiplon and ocinaplon, have entered into<br>
development, the latter with rather anxiolytic action.<br>
All these compounds show a rapid sleep induction and<br>
have less next-day hangover effects, lower potential<br>
for abuse and lower risk of rebound insomnia than<br>
benzodiazepines. The mechanism of action of these<br>
compounds is the alosteric activation of GABAA receptor<br><br>
through its binding to benzodiazepine binding site (C.<br>
F. P. George, The Lancet, 358, 1623-1626, 2001). While<br>
benzodiazepines are unspecific ligands at GABAA<br>
receptor binding site, Zolpidem and zaleplon show a<br>
greater selectivity for α1-subunit. Notwithstanding<br>
that, these drugs still affect the architecture of<br>
sleep and may induce dependence in long-term<br>
treatments.<br>
Zolpidem is disclosed in US 4382938. Some other related<br>
hypnotic imidazo[1,2-a]pyridines have been disclosed in<br>
FR 2593818, US 4650796 and EP 172096. In US 4626538<br>
(zaleplon), US 4654347, US 6399621 (indiplon) and EP<br>
129847 (ocinaplon) hypnotic pyrazolo[1,5-a]pyrimidines<br>
are disclosed. The use of N-[[(ethyl-4-phenyl)-2-<br>
imidazo[1,2-a]pyridinyl-3]methyl-N,3-dimethyl-<br>
butanamide, a compound previously disclosed in EP<br>
172096, has been claimed in the manufacturing of<br>
anesthetic medicaments in EP 430738.<br>
Research for new active compounds in the management of<br>
insomnia answers an underlying health need, because<br>
even recently introduced hypnotics still affect the<br>
architecture of sleep and may induce dependence in<br>
long-term treatments.<br>
It is therefore desirable to focus on the development<br>
of new hypnotic agents with a lower risk of side<br>
effects.<br><br>
Thus, the present invention is directed to new<br>
imidazo[1,2-a]pyridine compounds which are active<br>
versus GABAA and, particularly, versus its α1- and α2-<br>
subunits. Consequently, the compounds of this invention<br>
are useful in the treatment and prevention of all those<br>
diseases mediated by GABAA receptor α1- and α2-subunits.<br>
Non-limitative examples of such diseases are sleep<br>
disorders, preferably insomnia, anxiety and epilepsy.<br>
Non-limitative examples of the relevant indications of<br>
the compounds of this invention are all those diseases<br>
or conditions, such as insomnia or anesthesia, in which<br>
an induction of sleep, an induction of sedation or an<br>
induction of muscle relaxation are needed.<br>
Detailed description of the invention<br>
The present invention relates to novel imidazo[1,2-<br>
a]pyridine compounds of general formula (I):<br><br>
as well as pharmaceutically acceptable salts thereof;<br>
wherein<br>
R1 and R2 are independently selected from the group<br>
consisting of hydrogen, linear or branched alkyl(C1-<br><br>
C6), alkenyl (C2-C6) , alkynyl (C2-C6) , haloalkyl (C1-C6) , -<br>
O-alkyl(C1-C6), fluoro, chloro and bromo;<br>
R3 is selected from the group consisting of hydrogen,<br>
linear or branched alkyl (C1-C6) , cycloalkyl (C3-C6) ,<br>
cycloalkyl (C3-C6) alkyl (C1-C6) ,	alkenyl (C2-C6) ,<br>
alkenyl (C2-C6) alkyl (d-C6) , alkynyl (C2-C6) , alkynyl (C2-<br>
C6) alkyl (C1-C6) ;<br>
R4 is selected from the group consisting of hydrogen,<br>
haloalkyl (C2-C6) , cycloalkyl (C3-C5) , cycloalkyl (C3-<br>
C6) alkyl (d-C6) , alkynyl (C2-C6) alkyl (C1-C6) , alkyl (C1-C6)-<br>
O-alkyl (C1-C6) , alkyl (C1-C6) -NH-alkyl (C1-C6) , alkyl (C1-<br>
C6) -N (dialkyl (C1-C6) ) , -OR5, -NHR5, -NR5R6,<br><br>
phenylalkyl (C2-C6) , phenylalkenyl (C2-C6) , naphthyl,<br>
monosubstituted naphthyl, disubstituted naphthyl,<br>
naphthylalkyl (C1-C6) , naphthylalkenyl (C2-C6) , furyl,<br>
substituted furyl, benzofuryl, substituted benzofuryl,<br>
pyrrolyl, substituted pyrrolyl, isoxazolyl, substituted<br>
isoxazolyl, benzoisoxazolyl, substituted<br>
benzoisoxazolyl, imidazolyl, substituted imidazolyl,<br>
benzimidazolyl, substituted benzimidazolyl, indolyl,<br>
substituted indolyl, pyrazolyl, substituted pyrazolyl,<br>
thienyl, substituted thienyl, benzothienyl, substituted<br>
benzothienyl, thiazolyl, substituted thiazolyl,<br>
benzothiazolyl, substituted benzothiazolyl, quinolinyl,<br>
substituted quinolinyl, isoquinolinyl, substituted<br>
isoquinolinyl, pyridyl, substituted pyridyl, pyrazinyl,<br>
substituted	pyrazinyl,	6-oxo-1,4,5,6-<br>
tetrahydropyridazinyl, substituted 6-oxo-1,4,5,6-<br><br>
tetrahydropyridazinyl, thiadiazolyl, substituted<br>
thiadiazolyl, isothiazolyl, substituted isothiazolyl,<br>
thienylmethyl, 2-oxochromenyl, substituted 2-<br>
oxochromenyl, 2-(furan-2-yl)vinyl, oxazolyl,<br>
substituted oxazolyl, and benzisoxazolyl;<br>
Rs and R6 are independently selected from the group<br>
consisting of hydrogen, linear or branched alkyl(C1-<br>
C6) , phenylalkyl (C1-C6) , haloalkyl (C1-C6) , cycloalkyl(C3-<br>
C6) , cycloalkyl (C3-C6) alkyl (C1-C6) , alkenyl (C2-C6) and<br>
alkynyl (C2-C6) , alkenyl (C2-C6) alkyl (C1-C6) , alkynyl (C2-<br>
C6) alkyl (C1-C6), phenyl, substituted phenyl, heteroaryl,<br>
substituted heteroaryl; and<br>
R7 and R8 are independently selected from the group<br>
consisting of linear or branched alkyl (C2_C6),<br>
cycloalkyl (C3-C6) , alkenyl (C2-C6) , alkynyl (C2-C6) , -OH, -<br>
O-alkyl (C1-C6) , -SH, -S-alkyl (C1-C6) , halo-alkyl (C1-C6) ,<br>
ω,ω,ω-trifluoroalkyl (C1-C6) , -NHalkyl (C1-C6) ,<br>
Ndialkyl(C1-C6) , -NO2, -CN, -SO2alkyl (C1-C6) ,<br>
COalkyl (C1-C6) , -COOalkyl (C1-C6) , -CO-NHalkyl (C1-C6), -<br>
CONdialkyl(C1-C6),	phenyl, substituted phenyl,<br>
heteroaryl and substituted heteroaryl.<br>
The term "pharmaceutically acceptable salt" used herein<br>
encompasses any salt formed from organic and inorganic<br>
acids, such as hydrobromic, hydrochloric, phosphoric,<br>
nitric, sulfuric, acetic, adipic, aspartic,<br>
benzenesulfonic, benzoic, citric, ethanesulfonic,<br>
formic, fumaric, glutamic, lactic, maleic, malic,<br>
malonic, mandelic, methanesulfonic, 1,5-<br>
naphthalendisulfonic, oxalic, pivalic, propionic, p-<br>
toluenesulfonic, succinic, tartaric acids and the like.<br><br>
The term "substituted" used herein refers to the<br>
substitution of the corresponding radical or compound<br>
with at least one suitable substituent preferably<br>
selected from the group consisting of linear or<br>
branched alkyl (C2-C6) , cycloalkyl (C3-C6) , alkenyl (C2-C6) ,<br>
alkynyl (C2-C6) , -OH, -O-alkyl (C1-C6) , -SH, -S-alkyl (C1-<br>
C6) , halo-alkyl (C1-C6) , ω, ω, ω-trifluoroalkyl (C1-C6),<br>
NHalkyl (C1-C6) , -Ndialkyl (C1-C6) , -NO2, -CN,<br>
SO2alkyl(C1-C6) , -COalkyl (C1-C6) , -COOalkyl (C1-C6) , -CO-<br>
NHalkyl (C1-C6) , -CONdialkyl (C1-C6), phenyl, substituted<br>
phenyl, heteroaryl, substituted heteroaryl, fluoro,<br>
chloro and bromo.<br>
The preferred compounds of the present invention are<br>
shown below:<br>
Furan-2-carboxylic acid (6-methyl-2-p-tolyl-<br>
imidazo[1,2-a] pyridin-3-ylmethyl)-amide;<br>
Pyridine-2-carboxylic acid (6-methyl-2-p-tolyl-imidazo<br>
[1,2-a]pyridin-3-ylmethyl)-amide;<br>
Thiophene-2-carboxylic acid (6-methyl-2-p-tolyl-imidazo<br>
[1,2-a]pyridin-3-ylmethyl)-amide;<br>
Cyclopropanecarboxylic acid (6-methyl-2-p-tolyl-imidazo<br>
[1,2-a]pyridin-3-ylmethyl)-amide;<br>
5-Nitro-furan-2-carboxylic acid (6-methyl-2-p-tolyl-<br>
imidazo [1,2-a]pyridin-3-ylmethyl)-amide;<br>
3,5-Difluoro-pyridine-2-carboxylic acid (6-methyl-2-p-<br>
tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-amide;<br>
6-Methoxy-benzothiazole-2-carboxylic acid(6-methyl-2-p-<br>
tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-amide;<br><br>
4-Dimethylamino-N-methyl-N-(6-methyl-2-p-tolyl-imidazo<br>
[1,2-a]pyridin-3-ylmethyl)-benzamide;<br>
Cyclopropanecarboxylic acid methyl-(6-methyl-2-p-tolyl-<br>
imidazo[1,2-a]pyridin-3-ylmethyl)-amide;<br>
Pyridine-2-carboxylic acid methyl-(6-methyl-2-p-tolyl-<br>
imidazo[1,2-a]pyridin-3-ylmethyl)-amide;<br>
Thiophene-2-carboxylic acid methyl-(6-methyl-2-p-tolyl-<br>
imidazo[1,2-a]pyridin-3-ylmethyl)-amide;<br>
5-Nitro-furan-2-carboxylic acid methyl-(6-methyl-2-p-<br>
tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-amide;<br>
2-Chloro-N-methyl-N-(6-methyl-2-p-tolyl-imidazo[1,2-<br>
a]pyridin-3-ylmethyl)-isonicotinamide;<br>
Cyclobutanecarboxylic acid (6-methyl-2-p-tolyl-<br>
imidazo[1,2-a]pyridin-3-ylmethyl)-amide;<br>
5-Methyl-pyrazine-2-carboxylic acid (6-methyl-2-p-<br>
tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-amide;<br>
6-Oxo-1,4,5,6-tetrahydro-pyridazine-3-carboxylic acid<br>
(6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-<br>
amide;<br>
[1,2,3]Thiadiazole-4-carboxylic acid (6-methyl-2-p-<br>
tolyl-imidazo[1, 2-a]pyridin-3-ylmethyl)-amide;<br>
N-(6-Methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-<br>
ylmethyl)-2-thiophen-2-yl-acetamide;<br>
1-Methyl-1H-imidazole-2-carboxylic acid (6-methyl-2-p-<br>
tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-amide;<br>
Thiazole-4-carboxylic acid (6-methyl-2-p-tolyl-<br>
imidazo[1,2-a]pyridin-3-ylmethyl)-amide;<br>
2,5-Dimethyl-oxazole-4-carboxylic acid (6-methyl-2-p-<br>
tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-amide;<br>
3,5-Dimethyl-isoxazole-4-carboxylic acid (6-methyl-2-p-<br>
tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-amide;<br><br>
Thiazole-4-carboxylic acid methyl-(6-methyl-2-p-tolyl-<br>
imidazo[1,2-a]pyridin-3-ylmethyl)-amide;<br>
1-(4-Dimethylamino-phenyl)-3-(6-methyl-2-p-tolyl-<br>
imidazo[1,2-a]pyridin-3-ylmethyl)-urea;<br>
1-Ethyl-3-(6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-<br>
ylmethyl)-urea;<br>
1-Isopropyl-3-(6-methyl-2-p-tolyl-imidazo[1,2-<br>
a]pyridin-<br>
3-ylmethyl)-urea;<br>
1-Cyclopentyl-3-(6-methyl-2-p-tolyl-imidazo[1,2-<br>
a]pyridin-3-ylmethyl)-urea;<br>
1-Cyclohexyl-3-(6-methyl-2-p-tolyl-imidazo[1,2-<br>
a]pyridin-3-ylmethyl)-urea;<br>
1-(6-Methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-<br>
ylmethyl)-3-phenyl-urea;<br>
(6-Methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-<br>
carbamic acid p-tolyl ester;<br>
(6-Methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-<br>
carbamic acid prop-2-ynyl ester;<br>
(6-Methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-<br>
carbamic acid methyl ester;<br>
(6-Methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-<br>
carbamic acid benzyl ester;<br>
(6-Methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-<br>
carbamic acid 4-methoxy-phenyl ester;<br>
(6-Methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-<br>
carbamic acid ethyl ester;<br>
(6-Methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-<br>
carbamic acid phenyl ester; and<br>
(6-Methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-<br>
carbamic acid isopropyl ester.<br><br>
Another aspect of the present invention is to provide a<br>
process for preparing the compounds of formula (I) and<br>
their pharmaceutically acceptable salts.<br>
Another aspect of the present invention is to provide a<br>
method for treating or preventing diseases associated<br>
with GABAA receptor modulation in a mammal which<br>
comprises administering to said mammal an effective<br>
amount of a compound of formula (I) or a<br>
pharmaceutically acceptable salt thereof.<br>
Another aspect of the present invention is to provide a<br>
method for treating or preventing diseases associated<br>
with Α1-GABAA receptor modulation in a mammal which<br>
comprises administering to said mammal an effective<br>
amount of a compound of formula (I) or a<br>
pharmaceutically acceptable salt thereof.<br>
Another aspect of the present invention is to provide a<br>
method for treating or preventing diseases associated<br>
with α2-GABAA receptor modulation in a mammal which<br>
comprises administering to said mammal an effective<br>
amount of a compound of formula (I) or a<br>
pharmaceutically acceptable salt thereof.<br>
Another aspect of the present invention is to provide a<br>
method for treating or preventing anxiety in a mammal<br>
which comprises administering to said mammal an<br>
effective amount of a compound of formula (I) or a<br>
pharmaceutically acceptable salt thereof.<br><br>
Another aspect of the present invention is to provide a<br>
method for treating or preventing epilepsy in a mammal<br>
which comprises administering to said mammal an<br>
effective amount of a compound of formula (I) or a<br>
pharmaceutically acceptable salt thereof.<br>
Another aspect of the present invention is to provide a<br>
method for treating or preventing sleep disorders in a<br>
mammal which comprises administering to said mammal an<br>
effective amount of a compound of formula (I) or a<br>
pharmaceutically acceptable salt thereof.<br>
Another aspect of the present invention is to provide a<br>
method for treating or preventing insomnia in a mammal<br>
which comprises administering to said mammal an<br>
effective amount of a compound of formula (I) or a<br>
pharmaceutically acceptable salt thereof.<br>
Another aspect of the present invention is to provide a<br>
method for inducing sedation-hypnosis in a mammal which<br>
comprises administering to said mammal an effective<br>
amount of a compound of formula (I) or a<br>
pharmaceutically acceptable salt thereof.<br>
Another aspect of the present invention is to provide a<br>
method for inducing anesthesia in a mammal which<br>
comprises administering to said mammal an effective<br>
amount of a compound of formula (I) or a<br>
pharmaceutically acceptable salt thereof.<br><br>
Another aspect of the present invention is to provide a<br>
method for modulating the necessary time to induce<br>
sleep and its duration in a mammal which comprises<br>
administering to said mammal an effective amount of a<br>
compound of formula (I) or a pharmaceutically<br>
acceptable salt thereof.<br>
Another aspect of the present invention is to provide a<br>
method for inducing muscle relaxation in a mammal which<br>
comprises administering to said mammal an effective<br>
amount of a compound of formula (I) or a<br>
pharmaceutically acceptable salt thereof.<br>
Another aspect of the present invention is to provide a<br>
pharmaceutical composition containing a compound of<br>
formula (I) or a pharmaceutically acceptable salt<br>
thereof in association with therapeutically inert<br>
carriers.<br>
Another aspect of the present invention is to provide<br>
the use of a compound of formula (I) or a<br>
pharmaceutically acceptable salt thereof for preparing<br>
a medicament for treating or preventing diseases<br>
associated with GABAA receptor modulation.<br>
Another aspect of the present invention is to provide<br>
the use of a compound of formula (I) or a<br>
pharmaceutically acceptable salt thereof for preparing<br>
a medicament for treating or preventing diseases<br>
associated with α1-GABAA or α2-GABAA receptor<br>
modulation.<br><br>
Another aspect of the present invention is to provide<br>
the use of a compound of formula (I) or a<br>
pharmaceutically acceptable salt thereof for preparing<br>
a medicament for treating or preventing anxiety,<br>
epilepsy, sleep disorders, insomnia, for inducing<br>
sedation-hypnosis, anesthesia or muscle relaxation or<br>
for modulating the necessary time to induce sleep and<br>
its duration.<br>
The compounds of general formula (I) wherein R3 is<br>
hydrogen and R4 is a carbon group can be obtained<br>
following the synthetic strategy showed in Scheme 1.<br><br>
The imidazopyridine (IV) is obtained by cyclization<br>
between the corresponding aminopyridine (VII) and the<br>
bromoacetophenone (VIII). This reaction is carried out<br><br>
by heating both components at reflux for 2-8 hours,<br>
using a polar solvent such as methanol, ethanol,<br>
butanol and the like. The final product (IV) is<br>
obtained by evaporation of the crude and<br>
crystallization of the residue with the adequate<br>
solvent.<br>
The Mannich reaction between this imidazopyridine (IV)<br>
and formaldehyde in an acidic moiety, such as diluted<br>
acetic acid, yields the alcohol (II). The reaction is<br>
carried out by heating the mixture at 55°C for a period<br>
of 2-6 h. The solvent is removed and the residue thus<br>
obtained is suspended in dichloromethane, and stirred<br>
for 12 hours. The alcohol (II) is washed and dried.<br>
Finally, the condensation of the alcohol (II) and the<br>
appropriate nitrile (IX) yields compounds of general<br>
formula (I) , when R3 is hydrogen and R4 is a carbon<br>
group, by using sulphuric acid as catalyst and a polar<br>
solvent, such as acetic acid, acetonitrile,<br>
tetrahydrofurane and the like. The components are<br>
stirred and heated at reflux for 2-6 hours. The crude<br>
thus obtained is basified with ammonia and extracted<br>
with dichloromethane to yield the corresponding amide<br>
(I, R3 = H, R4 = carbon group).<br>
Once the amides (I, R3 = H, R4 = carbon group) are<br>
obtained, the nitrogen present in this functional group<br>
can be alkylated according to a procedure which is well<br>
known by an expert skilled in organic chemistry. The<br>
reaction is shown in Scheme 2.<br><br><br>
The reaction is done by using sodium hydride as base<br>
and dimethylformamide as solvent under inert<br>
atmosphere. The mixture is stirred at room temperature<br>
for 1 hour, and the crude thus obtained is removed with<br>
dichloromethane. The procedure yields the corresponding<br>
N-alkylated amides (I, R3 = carbon group, R4 = carbon<br>
group).<br>
We also report the preparation of urea compounds of<br>
general formula (I) when R3 is hydrogen and R4 is -NHR5.<br>
The synthetic strategy is shown in Scheme 3.<br><br><br>
In this case, the imidazopyridine (IV) described above<br>
is treated with (V) to yield the corresponding<br>
acetamide (VI). Q is selected from the group consisting<br>
of -OH, -Oalkyl (C1-C3) , -N+ (alkyl (C1-C3))3Cl-,<br>
N+(alkyl(C1-C3) )3Br-, -N+(alkyl (C1-C3))3I-, preferably<br>
OH. This reaction is carried out by using an acidic<br>
solvent such as acetic acid and an acid as catalyst.<br>
The reaction takes place at room temperature for 1-3<br>
hours and then at reflux for 2-4 hours. An extraction<br><br>
with an organic solvent yields the corresponding<br>
acetamide (VI).<br>
The hydrolysis of acetamides (VI) in acidic media leads<br>
to amines (III). The reaction takes place at reflux<br>
using a protic solvent such as methanol, ethanol,<br>
propanol, and the like, for a period of 30-90 min. The<br>
solvent is removed and the crude is neutralized and<br>
extracted with an organic solvent to obtain amines<br>
(III) . These amines are the precursors of urea<br>
compounds (I, R3 = H, R4 = -NHR5) .<br>
Finally, the coupling between amines (III) and<br>
isocyanates R5NCO yields the corresponding urea<br>
compounds (I, R3 = H, R4 = -NHR5) as mentioned above.<br>
The reaction is carried out by using the appropriate<br>
isocyanate, stirring at room temperature for 20-30<br>
hours, and using a basic solvent such as pyridine. The<br>
solvent is removed and the products are crystallized<br>
with the appropriate solvent.<br>
In parallel, amines (III) react with chloroformiates to<br>
yield carbamates of general formula (I) when R3 is<br>
hydrogen and R4 is -OR5, as shown in Scheme 4.<br><br><br>
The reaction takes place at room temperature for a<br>
period of 20-30 hours. The appropriate chloroformiate<br>
reacts by using a basic solvent such as pyridine. The<br>
solvent is removed and the products are crystallized<br>
with water, and filtered off. Thus, carbamates (I, R3 =<br>
H, R4 = -OR5) are obtained in good yields.<br><br>
From the compounds of general formula (I) it is<br>
possible to obtain their pharmaceutically acceptable<br>
salts by treatment with the corresponding acids.<br>
The applicants have discovered that the compounds of<br>
the present invention have a high affinity for α1- and<br>
α2- GABAA receptors as shown in Tables 1 and 2. These<br>
in vitro results are consistent with those in vivo<br>
results obtained in sedation-hypnosis tests (Table 3).<br>
In accordance with the results obtained, certain<br>
compounds of the present invention have surprisingly<br>
evidenced high affinity for α1-GABAA receptors and<br>
interesting pharmacological activity in vivo, which<br>
have been similar to or higher than those of prior-art<br>
compounds. Moreover, some of them displayed lower<br>
affinity for α2-GABAA receptors, indicating increased<br>
selectivity for α1-GABAA versus α2-GABAA receptors. All<br>
these results support their use in diseases or<br>
conditions, in which preferential activity on α1-GABAA<br>
is desirable, such as insomnia or anesthesia, in which<br>
an induction of sleep and an induction of sedation are<br>
needed. Furthermore, lost of righting reflex has been<br>
detected in some animals administered with certain<br>
compounds of the present invention, supporting their<br>
use as anesthetic agents. Indeed, certain compounds of<br>
the present invention have demonstrated interesting<br>
affinity for α2-GABAA receptors, which has been similar<br>
to or higher than that of prior-art compounds. These<br>
results support their use in diseases or conditions in<br>
which preferential activity on α2-GABAA receptors is<br><br>
desirable, such as anxiety or in which an induction of<br>
muscle relaxation is needed.<br>
The pharmacological activity of the compounds of the<br>
present invention has been determined as shown below.<br>
Ligand-binding assays. Determination of the<br>
affinity of test compounds for α1- and α2-GABAA<br>
receptor.<br>
Male Sprague-Dawley rats weighing 200-250 g at the time<br>
of experiment were used. After decapitation of the<br>
animal, the cerebellum (tissue that mostly contains α1-<br>
GABAA receptor) and spinal cord (tissue that mostly<br>
contains α2-GABAA receptor) were removed. The membranes<br>
were prepared according to the method by J. Lameh et<br>
al.(Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 24,<br>
979-991, 2000) and H. Noguchi et al. (Eur. J. Pharm.,<br>
434, 21-28, 2002). Once the tissues weighed, they were<br>
suspended in 50 mM Tris HCl (pH 7.4), 1:40 (w/v) , or<br>
sucrose 0.32 M in the case of spinal cord, homogenized<br>
and then centrifuged at 20,000 g for 10 min at 7°C<br>
twice. The resulting pellet was resuspended under the<br>
same conditions and centrifuged again. The pellet was<br>
finally resuspended on a minimum volume and kept at -<br>
80°C overnight. On the next day, the process was<br>
repeated until the final pellet was resuspended at a<br>
ratio of 1:10 (w/v) in the case of cerebellum and at a<br>
ratio of 1:5 (w/v) in the case of spinal cord.<br>
Affinity was determined by competitive tests using<br>
radiolabeled flumazenil as ligand. The tests were<br><br>
performed according to the methods described by S.<br>
Arbilla et al. (Eur. J. Pharmacol., 130, 257-263,<br>
1986); and Y. Wu et al. (Eur. J. Pharmacol., 278, 125-<br>
132, 1995) using 96-well microtiter plates. The<br>
membranes containing the study receptors, flumazenil<br>
(radiolabeling at a final concentration of 1 nM) and<br>
ascending concentrations of test compounds (in a total<br>
volume of 230 µL in 50 mM [ph 7.4] Tris.HCl buffer)<br>
were incubated. Simultaneously, the membranes were only<br>
incubated with the radiolabeled flumazenil, (total<br>
binding, 100%) and in the presence of an elevated<br>
concentration of unradiolabeled flumazenil (non-<br>
specific binding, % estimation of radiolabeled ligand).<br>
The reactions started on adding the radiolabeled ligand<br>
followed by incubation for 60 minutes at 4°C. At the<br>
end of the incubation period, 200 µL of reaction were<br>
transferred to a multiscreen plate (Millipore) and<br>
filtered using a vacuum manifold and then washed three<br>
times with cold test buffer. The multiscreen plates<br>
were equipped with a GF/B filter that retained the<br>
membranes containing the receptors and the radiolabeled<br>
ligand which has been bound to the receptors. After<br>
washing, the plates were left till dry. Once dried,<br>
scintillation liquid was added and left under stirring<br>
overnight. The next day the plates were counted using a<br>
Perkin-Elmer Microbeta scintillation counter.<br>
For analysis of the results the percentage of specific<br>
binding for every concentration of test compound was<br>
calculated as follows:<br><br>
% specific binding = (X-N/T-N) x 100<br>
where,<br>
X: amount of bound ligand for every concentration of<br>
compound.<br>
T: total binding, maximum amount bound to the<br>
radiolabeled ligand.<br>
N: non-specific binding, amount of radiolabeled<br>
ligand bound in a non-specific way irrespective of the<br>
receptor used.<br>
Every concentrations of compound were tested in<br>
triplicate and their mean values were used to determine<br>
the experimental values of % specific binding versus<br>
the concentration of compound. Affinity data are<br>
expressed as % inhibition at 10-5M and 10-7M<br>
concentrations. The results of these tests are given in<br>
Tables 1 and 2.<br><br><br><br><br><br><br><br><br>
In vivo determination of predictive sedative-hypnotic<br>
action.<br>
The in vivo effects of these compounds were assessed by<br>
a predictive sedation-hypnosis test in mice (D. J.<br>
Sanger et al., Eur.J.Pharmacol., 313, 35-42, 1996/ and<br>
G. Griebel et al., Psychopharmacology, 146, 205-213,<br>
1999).<br>
Groups of 5-8 male CD1 mice, weighing 22-26 g at the<br>
time of test, were used. The test compounds were<br>
administered in single equimolecular intraperitoneal<br>
doses, suspended in 0.25% agar with one drop of Tween<br>
in a volume of 10 mL/kg. Control animals received the<br>
vehicle alone. Using a Smart System (Panlab,S.L.,<br>
Spain) the traveled distance in cm is recorded for each<br>
mouse at 5-min intervals during a period of 30 minutes<br>
after dosing. The inhibition percentage of traveled<br>
distance of treated animals versus control animals (the<br>
first 5 min were discarded) was calculated. The results<br>
of this test are given in Table 3.<br>
Table 3. Determination of in vivo sedative-hypnotic<br>
activity in mice.<br><br><br><br><br><br>
The following non-limiting examples illustrate the<br>
scope of the present invention.<br>
Example 1: 6-Methyl-2-p-tolyl-imidazo[1,2-a]pyridin-4-<br>
ium bromide<br><br>
A solution of 11.53 g (106.7 mmol) of 5-methyl-pyridin-<br>
2-ylamine in 150 mL of ethanol is added to a solution<br>
of 25 g (117.3 mmol) of 2-bromo-1-p-tolyl-ethanone in<br>
150 mL of ethanol. The resulting solution is stirred at<br>
reflux for 4 hours. The reaction is allowed to cool,<br>
and the solvent is removed in vacuo. The yellow solid<br>
obtained is dissolved in 30 mL of hot ethanol, and 40<br><br>
mL of acetone are added. The solid obtained is filtered<br>
off, washed with acetone and dried over calcium<br>
chloride to give 20.0 g (65.9 mmol, yield: 62%) of 6-<br>
methyl-2-p-tolyl-imidazo[1,2-a]pyridin-4-ium bromide as<br>
a white solid.<br>
1H NMR (400 MHz, DMSO-d6) : δ 8.31-7.10 (Ar, 8H, m) ,<br>
2.36 (Ph-Me, 3H, s), 2.31 (Me, 3H, s).<br>
MS (ES) m/z = 223 (MH+)<br>
HPLC = 100%<br>
Example 2: (6-Methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-<br>
yl)-methanol<br><br>
A solution of 6 mL (81 mmol) of formaldehyde in water<br>
(37%) is added to a solution of 4 g (18 mmol) of 6-<br>
methyl-2-p-tolyl-imidazo[1,2-a]pyridin-4-ium bromide in<br>
30 mL of acetic acid. The reaction is heated at 55°C<br>
for 4 h. The resulting solution is allowed to cool, and<br>
the solvent is removed in vacuo. To the corresponding<br>
residue are added 20 mL of ammonia (25%) and 30 mL of<br>
dichloromethane, and the suspension is stirred<br>
overnight. The solid obtained is filtered off, washed<br>
with dichloromethane and water and dried over calcium<br>
chloride, to yield 2.8 g (11 mmol, 62%) of (6-methyl-2-<br>
p-tolyl-imidazo[1,2-a]pyridin-3-yl)-methanol as a white<br>
solid.<br><br>
1H NMR (400 MHz, DMSO-d6) : δ 8.23-7.13 (Ar, 7H, m) ,<br>
5.33 (OH, 1H, t, J= 5.2 Hz), 4.85 (CH2, 2H, d, J= 5.2<br>
Hz), 2.35 (Ph-Me, 3H, s), 2.33 (Me, 3H, s).<br>
MS (ES) m/z = 253 (MH+)<br>
HPLC = 98.3%<br>
Example 3: 4-Dimethylamino-N-(6-methyl-2-p-tolyl-<br>
imidazo [1,2-a]pyridin-3-ylmethyl)-benzamide<br><br>
To a solution of 1 eq of (6-methyl-2-p-tolyl-<br>
imidazo[1,2-a]pyridin-3-yl)-methanol in acetic acid is<br>
added a solution of 4-dimethylaminobenzonitrile (2 eq)<br>
in acetic acid. Then, 4 eq of sulphuric acid are added<br>
slowly. The mixture is heated at room temperature for<br>
1.5 h, and then at reflux for 2 h. The reaction is<br>
allowed to cool and is basified with ammonia (25%). The<br>
suspension is extracted with dichloromethane. The<br>
organic phase is dried over magnesium sulphate and<br>
filtered off. The solvent is removed in vacuo to give<br>
0.96 eq of 4-Dimethylamino-N-(6-methyl-2-p-tolyl-<br>
imidazo[1,2-a]pyridin-3-ylmethyl)-benzamide.<br>
1H NMR (400 MHz, DMSO-d6) : δ 8.58 (NH, 1H, t, J= 5.2<br>
Hz), 8.29-6.65 (Ar, 11H, m) , 4.87 (CH2, 2H, d, J= 5.2<br>
Hz), 2.94 (N-Me, 6H, s), 2.34 (Ph-Me, 3H, s).<br><br>
MS (ES) m/z = 399 (MH+)<br>
HPLC = 97.1%<br>
The compounds of examples 4-21 were prepared according<br>
to this procedure starting from (6-methyl-2-p-tolyl-<br>
imidazo[1,2-a]pyridin-3-yl)-methanol and the<br>
corresponding nitrile.<br>
Example 4: Furan-2-carboxylic acid (6-methyl-2-p-tolyl-<br>
imidazo[1,2-a]pyridin-3-ylmethyl)-amide<br><br>
Yield: 47%<br>
1H NMR (400 MHz, DMSO-d6) : δ 8.17 (NH, 1H, m) , 7.65-<br>
6.11 (Ar, 10H, m) , 4.51 (CH2, 2H, m) , 2.33 (Ph-Me, 3H,<br>
s), 2.29 (Me, 3H, s).<br>
MS (ES) m/z = .346 (MH+)<br>
HPLC = 82.7%<br>
Example 5: Pyridine-2-carboxylic acid (6-methyl-2-p-<br>
tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-amide<br><br><br>
Yield: 17%<br>
1H NMR (400 MHz, DMSO-d6) : 5 9.36 (NH, 1H, t, J= 5.6<br>
Hz), 8.61-7.12 (Ar, 14H, m) , 4.95 (CH2, 2H, d, J= 5.6<br>
Hz), 2.34 (Ph-Me, 3H, s), 2.29 (Me, 3H, s).<br>
MS (ES) m/z = 357 (MH+)<br>
HPLC = 96.7%<br>
Example 6: 1,5-Dimethyl-1H-pyrrole-2-carboxylic acid<br>
(6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-<br>
amide<br><br>
Yield: 14%<br>
1H NMR (400 MHz, DMSO-d6) : 8 8.31 (NH, 1H, m) , 7.66-<br>
6.99 (Ar, 9H, m) , 4.64 (CH2, 2H, m) , 3.28 (N-Me, 3H,<br>
s), 2.34 (Ph-Me, 3H, s) , 2.17 (Me, 3H, s) , 1.34 (Me-<br>
pyrrole, 3H, s).<br>
MS (ES) m/z = 373 (MH+)<br>
HPLC = 97.9%<br>
Example 7: N-(6-Methyl-2-p-tolyl-imidazo[1, 2-a]pyridin-<br>
3-ylmethyl)-isonicotinamide<br><br><br>
Yield: 19%<br>
1H NMR (400 MHz, DMSO-d6): 8 9.23 (NH, 1H, t, J= 4.8<br>
Hz), 8.70-7.14 (Ar, 11H, m) , 4.93 (CH2, 2H, d, J= 4.8<br>
Hz), 2.34 (Ph-Me, 3H, s), 2.3 (Me, 3H, s).<br>
MS (ES) m/z = 357 (MH+)<br>
HPLC = 92.9%<br>
Example 8: N-(6-Methyl-2-p-tolyl-imidazo[1,2-a]pyridin-<br>
3-ylmethyl)-4-nitro-benzamide<br><br>
Yield: 29%<br>
1H NMR (400 MHz, DMSO-d6) : δ 9.28 (NH, 1H, t, J= 3.6<br>
Hz), 8.29-7.14 (Ar, 11H, m) , 4.94 (CH2, 2H, d, J= 3.6<br>
Hz), 2.34 (Ph-Me, 3H, s), 2.3 (Me, 3H, s).<br>
MS (ES) m/z = 401 (MH+)<br>
HPLC = 98.8%<br>
Example 9: Thiophene-2-carboxylic acid (6-methyl-2-p-<br>
tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-amide<br><br><br>
Yield: 8%<br>
1H NMR (400 MHz, DMSO-d6) : δ 8.94 (NH, 1H, t, J= 5.2<br>
Hz), 8.26-7.10 (Ar, 10H, m) , 4.89 (CH2, 2H, d, J= 5.2<br>
Hz), 2.34 (Ph-Me, 3H, s), 2.3 (Me, 3H, s).<br>
MS (ES) m/z = 362 (MH+)<br>
HPLC = 92.1%<br>
Example 10: N-(6-Methyl-2-p-tolyl-imidazo[1,2-<br>
a]pyridin-3-ylmethyl)-4-trifluoromethyl-benzamide<br><br>
Yield: 89%<br>
1H NMR (400 MHz, DMSO-d6) : δ 9.18 (NH, 1H, t, J= 5.2<br>
Hz), 8.27-7.14 (Ar, 11H, m) , 4.94 (CH2, 2H, d, J= 5.2<br>
Hz), 2.34 (Ph-Me, 3H, s), 2.3 (Me, 3H, s).<br>
MS (ES) m/z = 424 (MH+)<br>
HPLC = 98.5%<br>
Example 11: 4-Methoxy-N-(6-methyl-2-p-tolyl-<br>
imidazo[1,2-a]pyridin-3-ylmethyl)-benzamide<br><br><br>
Yield: 14%<br>
1H NMR (400 MHz, DMSO-d6) : δ 8.8 (NH, 1H, t, J= 5.2<br>
Hz), 8.28-6.95 (Ar, 11H, m) , 4.89 (CH2, 2H, d, J= 5.2<br>
Hz), 3.78 (MeO, 3H, s), 2.34 (Ph-Me, 3H, s), 2.29 (Me,<br>
3H, s) .<br>
MS (ES) m/z = 386 (MH+)<br>
HPLC = 98.3%<br>
Example 12: 4-Acetyl-N-(6-methyl-2-p-tolyl-imidazo[1,2-<br>
a] pyridin-3-ylmethyl)-benzamide<br><br>
Yield: 17%<br>
1H NMR (400 MHz, DMSO-d6) : δ 9.14 (NH, 1H, t, J= 4.8<br>
Hz), 8.28-7.14 (Ar, 11H, m) , 4.93 (CH2, 2H, d, J= 4.8<br>
Hz), 2.6 (Me-CO, 3H, s), 2.34 (Ph-Me, 3H, s), 2.3 (Me,<br>
3H, s) .<br>
MS (ES) m/z = 398 (MH+)<br>
HPLC = 94.9%<br>
Example 13: Cyclopropanecarboxylic acid (6-methyl-2-p-<br>
tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-amide<br><br><br>
Yield: 60%<br>
1H NMR (400 MHz, DMSO-d6) : δ 8.6 (NH, 1H, t, J= 5.2<br>
Hz), 8.16-7.13 {Ar, 7H, m) , 4.72 (CH2, 2H, d, J= 5.2<br>
Hz), 2.35 (Ph-Me, 3H, s) , 2.3 (Me, 3H, s), 1.59 (CH,<br>
1H, m), 0.76 (CH2CH2, 4H, m).<br>
MS (ES) m/z = 320 (MH+)<br>
HPLC = 99.3%<br>
Example 14: 5-Nitro-furan-2-carboxylic acid (6-methyl-<br>
2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-amide<br><br>
Yield: 27%<br>
1H NMR (400 MHz, DMSO-d6) : δ 9.38 (NH, 1H, m) , 8.25-<br>
7.15 (Ar, 9H, m), 4.91 (CH2, 2H, d, J= 4 Hz), 2.34 (Ph-<br>
Me, 3H, s), 2.3 (Me, 3H, s).<br>
MS (ES) m/z = 391 (MH+)<br>
HPLC = 97.9%<br><br>
Example 15: 3-Methyl-furan-2-carboxylic acid (6-methyl-<br>
2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-amide<br><br>
Yield: 3%<br>
1H NMR (400 MHz, DMSO-d6) : δ 8.74 (NH, 1H, t, J= 5.2<br>
Hz), 8.25-6.21 (Ar, 9H, m) , 5.85 {CH2, 2H, d, J= 5.2<br>
Hz), 2.34 (Ph-Me, 3H, s) , 2.29 (Me, 3H, s) , 1.03 (Me-<br>
furane, 3H, s).<br>
MS (ES) m/z = 360 (MH+)<br>
HPLC = 93.7%<br>
Example 16: 3-Methyl-thiophene-2-carboxylic acid (6-<br>
methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-<br>
amide<br><br>
Yield: 29%<br>
1H NMR (400 MHz, DMSO-d6) : δ 8.6 (NH, 1H, m) , 8.3-6.9<br>
(Ar, 9H, m) , 4.87 (CH2, 2H, d, J= 5.2 Hz), 2.37 (Me,<br>
3H, s), 2.34 (Ph-Me, 3H, s), 2.3 (Me, 3H, s).<br>
HPLC = 87.1%<br><br>
Example 17: 2-Chloro-N-(6-methyl-2-p-tolyl-imidazo[1,2-<br>
a]pyridin-3-ylmethyl)-isonicotinamide<br><br>
Yield: 15%<br>
1H NMR (400 MHz, DMSO-d6) : δ 9.29 (NH, 1H, m) , 8.56-<br>
7.16 (Ar, 10H, m) , 4.92 (CH2, 2H, d, J= 4.4 Hz), 2.34<br>
(Ph-Me, 3H, s), 2.31 (Me, 3H, s).<br>
HPLC = 99.2%<br>
Example 18: 2,3,5,6-Tetrafluoro-N-(6-methyl-2-p-tolyl-<br>
imidazo[1,2-a]pyridin-3-ylmethyl)-isonicotinamide<br><br>
Yield: 13%<br>
1H NMR (400 MHz, DMSO-d6) : δ 9.65 (NH, 1H, m) , 8.19<br>
(Ar, 7H, m) , 4.99 (CH2, 2H, m) , 2.36 (Ph-Me, 3H, s) ,<br>
2.32 (Me, 3H, s).<br>
HPLC = 96.9%<br>
Example 19: Quinoline-2-carboxylic acid (6-methyl-2-p-<br>
tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-amide<br><br><br>
Yield: 17%<br>
1H NMR (400 MHz, DMSO-d6) : δ 9.47 <nh t j="4.8&lt;br/">
Hz), 8.57-7.13 (Ar, 13H, m) , 5.05 (CH2, 2H, d, J= 4.8<br>
Hz), 2.34 (Ph-Me, 3H, s), 2.29 (Me, 3H, s).<br>
MS (ES) m/z = 407 (MH+)<br>
HPLC = 90.5%<br>
Example 20: 3,5-Difluoro-pyridine-2-carboxylic acid (6-<br>
methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-<br>
amide <br>
Yield: 86%<br>
1H NMR (400 MHz, DMSO-d6) : δ 9.28 (NH, 1H, t, J= 5.2<br>
Hz), 8.54-7.14 (Ar, 9H, m) , 4.92 (CH2, 2H, d, J= 5.2<br>
Hz), 2.35 (Ph-Me, 3H, s), 2.3 (Me, 3H, s).<br>
MS (ES) m/z = 393 (MH+)<br>
HPLC = 96.6%<br><br>
Example 21: 6-Methoxy-benzothiazole-2-carboxylic acid<br>
(6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-<br>
amide<br><br>
Yield: 10%<br>
1H NMR (400 MHz, DMSO-d6) : δ 8.18 (NH, 1H, m) , 8.02-<br>
7.12 (Ar, 10H, m) , 4.67 (CH2, 2H, m) , 4.06 (MeO, 3H,<br>
s), 2.27 (Ph-Me, 3H, s), 2.17 (Me, 3H, s).<br>
MS (ES) m/z = 443 (MH+)<br>
HPLC = 100%<br>
Example 22: 4-Dimethylamino-N-methyl-N-(6-methyl-2-p-<br>
tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-benzamide<br><br>
To a solution of 4-dimethylamino-N-(6-methyl-2-p-tolyl-<br>
imidazo[1,2-a]pyridin-3-ylmethyl)-benzamide (1 eq) in<br>
dry DMF are added 1.2 eq of NaH (60%) under argon. The<br>
suspension is stirred for 10 min at room temperature.<br>
Then 1.1 eq of Mel are added and the corresponding<br><br>
mixture is stirred for 1 h at room temperature. After<br>
this period, 0.5 N NaOH is added. The mixture is<br>
extracted with dichloromethane. The organic layer is<br>
dried over magnesium sulphate and the solvent is<br>
removed in vacuo to obtain 0.58 eq of 4-dimethylamino-<br>
N-methyl-N-(6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-<br>
ylmethyl)-benzamide.<br>
1H NMR (400 MHz, DMSO-d6) : δ 8.23-6.67 (Ar, 11H, m) ,<br>
5.19 (CH2, 2H, s), 2.92 (NMe2, 6H, s) , 2.58 (N-Me, 3H,<br>
s), 2.34 (Ph-Me, 3H, s), 2.28 (Me, 3H, s).<br>
MS (ES) m/z = 413 (MH+)<br>
HPLC = 90.8%<br>
The compounds of examples 23-36 were prepared following<br>
this procedure starting from the corresponding N-<br>
dealkylated amides.<br>
Example 23: 4-Isobutyryl-N-methyl-N-(6-methyl-2-p-<br>
tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-benzamide<br><br>
Yield: 20%<br>
1H NMR (400 MHz, DMSO-d6) : δ 8.31-7.18 (Ar, 11H, m) ,<br>
5.27 (CH2, 2H, s), 3.64 (CH, 1H, hept, J= 6.8 Hz), 2.46<br>
(N-Me, 3H, s), 2.35 (Ph-Me, 3H, s) , 2.32 (Me, 3H, s),<br>
1.09 (Me, 6H, d, J= 6.8 Hz).<br><br>
MS (ES) m/z = 440 (MH+)<br>
HPLC = 83.7%<br>
Example 24: Cyclopropanecarboxylic acid methyl-(6-<br>
methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-<br>
amide<br><br>
Yield: 100%<br>
1H NMR (400 MHz, DMSO-d6) : δ 8.08-7.14 (Ar, 7H, m) ,<br>
5.09 (CH2, 2H, s), 2.72 (N-Me, 3H, s), 2.35 (Ph-Me, 3H,<br>
s), 2.25 (Me, 3H, s) , 1.89 (CH, 1H, m) , 0.8 (CH2, 4H,<br>
m) .<br>
MS (ES) m/z = 334 (MH+)<br>
HPLC = 98.6%<br>
Example 25: 4-Methoxy-N-methyl-N-(6-methyl-2-p-tolyl-<br>
imidazo[1,2-a]pyridin-3-ylmethyl)-benzamide<br><br>
Yield: 93%<br>
1H NMR (400 MHz, DMSO-d6) : δ 9.45-7.68 (Ar, 11H, m) ,<br>
5.2 (CH2, 2H, s), 3.77 (MeO, 3H, s), 2.55 (N-Me, 3H,<br>
s), 2.35 (Ph-Me, 3H, s), 2.3 (Me, 3H, m).<br><br>
MS (ES) m/z = 400 (MH+)<br>
HPLC = 95%<br>
Example 26: N-Methyl-N-(6-methyl-2-p-tolyl-imidazo[1,2-<br>
a] pyridin-3-ylmethyl)-4-trifluoromethyl-benzamide<br><br>
Yield: 100%<br>
1H NMR (400 MHz, DMSO-d6) : δ 8.30-7.18 (Ar, 11H, m) ,<br>
5.27 (CH2, 2H, s), 2.5 (N-Me, 3H, s) , 2.35 (Ph-Me, 3H,<br>
s), 2.32 (Me, 3H, s).<br>
MS (ES) m/z = 438 (MH+)<br>
HPLC = 95.9%<br>
Example 27: N-Methyl-N-(6-methyl-2-p-tolyl-imidazo[1,2-<br>
a] pyridin-3-ylmethyl)-isonicotinamide<br><br>
Yield: 22%<br>
1H NMR (400 MHz, DMSO-d6) : δ 8.63-7.19 (Ar, 11H, m) ,<br>
5.25 (CH2, 2H, s), 2.46 (N-Me, 3H, s), 2.35 (Ph-Me, 3H,<br>
s) , 2.32 (Me, 3H, s) .<br><br>
MS (ES) m/z = 371 (MH+)<br>
HPLC = 94.6%<br>
Example 28: Pyridine-2-carboxylic acid methyl-(6-<br>
methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-<br>
amide<br><br>
Yield: 77%<br>
1H NMR (400 MHz, DMSO-d6) : δ 8.53-7.18 (Ar, 11H, m) ,<br>
5.27 (CH2, 2H, s), 2.54 (N-Me, 3H, s), 2.33 (Ph-Me, 3H,<br>
s), 2.3 (Me, 3H, s).<br>
MS (ES) m/z = 371 (MH+)<br>
HPLC = 80.6%<br>
Example 29: Thiophene-2-carboxylic acid methyl-(6-<br>
methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-<br>
amide<br><br>
Yield: 100%<br>
1H NMR (400 MHz, DMSO-d6) : δ 8.22-7.09 (Ar, 10H, m) ,<br>
5.26 (CH2, 2H, s), 2.77 (N-Me, 3H, s), 2.34 (Ph-Me, 3H,<br>
s), 2.28 (Me, 3H, s).<br><br>
MS (ES) m/z = 376 (MH+)<br>
HPLC = 87%<br>
Example 30: 4,N-Dimethyl-N-(6-methyl-2-p-tolyl-imidazo<br>
[1,2-a]pyridin-3-ylmethyl)-benzamide<br><br>
Yield: 83%<br>
1H NMR (400 MHz, DMSO-d6) : δ 7.67-7.16 (Ar, 11H, m) ,<br>
5.22 (CH2, 2H, s), 2.52 (N-Me, 3H, s) , 2.34 (Ph-Me, 3H,<br>
s), 2.31 (Ph-Me, 3H, s), 2.3 (Me, 3H, s).<br>
MS (ES) m/z = 384 (MH+)<br>
HPLC = 99%<br>
Example 31: N-Methyl-N-(6-methyl-2-p-tolyl-imidazo[1,2-<br>
a] pyridin-3-ylmethyl)-4-nitro-benzamide<br>
Yield: 48% <br>
1H NMR (400 MHz, DMSO-d6) : δ 8.30-7.19 (Ar, 11H, m) ,<br>
5.27 (CH2, 2H, s), 2.49 (N-Me, 3H, s), 2.34 (Ph-Me, 3H,<br>
s), 2.32 (Me, 3H, s).<br><br>
MS (ES) m/z = 415 (MH+)<br>
HPLC = 100%<br>
Example 32: 5-Nitro-furan-2-carboxylic acid methyl-(6-<br>
methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-<br>
amide<br><br>
Yield: 42%<br>
1H NMR (400 MHz, DMSO-d6) : δ 8.26-7.19 (Ar, 9H, m) ,<br>
5.26 (CH2, 2H, s), 2.82 (N-Me, 3H, s), 2.34 (Ph-Me, 3H,<br>
s), 2.3 (Me, 3H, s).<br>
MS (ES) m/z = 405 (MH+)<br>
HPLC = 98.8%<br>
Example 33: 3,5-Difluoro-pyridine-2-carboxylic acid<br>
methyl-(6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-<br>
ylmethyl)-amide<br><br>
Yield: 27%<br><br>
1H NMR (400 MHz, DMSO-d6) : δ 8.55-7.20 (Ar, 9H, m) , 5.3<br>
(CH2, 2H, s), 2.46 (N-Me, 3H, s) , 2.34 (Ph-Me, 3H, s) ,<br>
2.3 (Me, 3H, s).<br>
MS (ES) m/z = 407 (MH+)<br>
HPLC = 96.6%<br>
Example 34: 2-Chloro-N-methyl-N-(6-methyl-2-p-tolyl-<br>
imidazo [1,2-a]pyridin-3-ylmethyl)-isonicotinamide<br><br>
Yield: 61%<br>
1H NMR (400 MHz, DMSO-d6) : δ 8.51-7.22 (Ar, 10H, m) ,<br>
5.26 (CH2, 2H, s), 2.48 (N-Me, 3H, s), 2.38 (Ph-Me, 3H,<br>
s), 2.36 (Me, 3H, s).<br>
MS (ES) m/z = 405 (MH+)<br>
HPLC = 83.6%<br>
Example 35: Quinoline-2-carboxylic acid methyl-(6-<br>
methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-<br>
amide<br><br><br>
Yield: 60%<br>
1H NMR (400 MHz, DMSO-d6) : δ 8.77-7.16 (Ar, 13H, m) ,<br>
5.35 (CH2, 2H, s), 2.65 (N-Me, 3H, s), 2.36 (Ph-Me, 3H,<br>
s), 2.33 (Me, 3H, s).<br>
MS (ES) m/z = 421 (MH+)<br>
HPLC = 96.6%<br>
Example 36: 6-Methoxy-3-methyl-2-[methyl-(6-methyl-2-p-<br>
tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-carbamoyl]-<br>
benzothiazol-3-ium iodide<br><br>
Yield: 85%<br>
1H NMR (400 MHz, DMSO-d6) : δ 8.53-7.29 (Ar, 10H, m) ,<br>
4.73 (CH2, 2H, s), 3.94 (MeO, 3H, s) , 3.44 (Me-<br>
thiazole, 3H, s),	2.97 (N-Me, 3H, s), 2.37 (Ph-Me, 3H,<br>
s), 2.32 (Me, 3H,	s).<br>
MS (ES) m/z = 471	(MH+)<br>
HPLC = 97.6%<br>
Example 37: N-Ethyl-N-(6-methyl-2-p-tolyl-imidazo[1,2-<br>
a] pyridin-3-ylmethyl)-4-trifluoromethyl-benzamide<br><br><br>
To a solution of N-(6-methyl-2-p-tolyl-imidazo[1,2-<br>
a]pyridin-3-ylmethyl)-4-trifluoromethyl-benzamide (1<br>
eq) in dry DMF are added 1.2 eq of NaH (60%) under<br>
argon. The suspension is stirred for 10 min at room<br>
temperature. Then 1.1 eq of EtI are added and the<br>
corresponding mixture is stirred for 1 h at room<br>
temperature. After this period, 0.5 N NaOH is added.<br>
The mixture is extracted with dichloromethane. The<br>
organic layer is dried over magnesium sulphate and the<br>
solvent is removed in vacuo to obtain 0.47 eq of N-<br>
ethyl-N-(6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-<br>
ylmethyl)-4-trifluoromethyl-benzamide.<br>
Yield: 47%<br>
1H NMR (400 MHz, DMSO-d6) : δ 8.26-7.19 (Ar, 11H, m) ,<br>
5.32 (CH2, 2H, s), 2.7 (CH2-Me, 2H, m) , 2.36 (Ph-Me,<br>
3H, s), 2.33 (Me, 3H, s), 0.55 (Me-CH2, 3H, m) .<br>
MS (ES) m/z = 452 (MH+)<br>
HPLC = 99.8%<br>
The compound of example 38 was prepared according to<br>
this procedure starting from the corresponding N-<br>
dealkylated amide.<br><br>
Example 38: Cyclopropanecarboxylic acid ethyl-(6-<br>
methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-<br>
amide<br><br>
Yield: 41%<br>
1H NMR (400 MHz, DMSO-d6) : δ 8.07-7.14 (Ar, 7H, m) ,<br>
5.12 (CH2, 2H, s), 3.08 (CH2-Me, 2H, q, J= 7.2 Hz),<br>
2.36 (Ph-Me, 3H, s) , 2.25 (Me, 3H, s) , 1.85 (CH, 3H,<br>
m) , 0.81 (Me-CH2, 3H, t, J= 7.2 Hz), 0.73 (CH2, 4H, m) .<br>
MS (ES) m/z = 348 (MH+)<br>
HPLC = 92.3%<br>
Example 39: N-(6-Methyl-2-p-tolyl-imidazo[1,2-<br>
a]pyridin-3-ylmethyl)-N-propyl-4-trifluoromethyl-<br>
benzamide<br><br>
To a solution of N-(6-methyl-2-p-tolyl-imidazo[1,2-<br>
a]pyridin-3-ylmethyl)-4-trifluoromethyl-benzamide (1<br>
eq) in dry DMF are added 1.2 eq of NaH (60%) under<br>
argon. The suspension is stirred for 10 min at room<br>
temperature. Then 1.1 eq of PrI are added and the<br>
corresponding mixture is stirred for 1h at room<br><br>
temperature. After this period, 0.5 N NaOH is added.<br>
The mixture is extracted with dichloromethane. The<br>
organic layer is dried over magnesium sulphate and the<br>
solvent is removed in vacuo to obtain 0.17 eq of N-(6-<br>
methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-N-<br>
propyl-4-trifluoromethyl-benzamide.<br>
Yield: 17%<br>
MS (ES) m/z = 466 (MH+)<br>
HPLC = 83.9%<br>
The compound of example 40 was prepared according to<br>
this procedure starting from the corresponding N-<br>
dealkylated amide.<br>
Example 40: Cyclopropanecarboxylic acid (6-methyl-2-p-<br>
tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-propyl-amide<br><br>
Yield: 35%<br>
MS (ES) m/z = 362 (MH+)<br>
HPLC = 89.8%<br>
Example 41: N-(6-methyl-2-p-tolyl-imidazo[1,2-<br>
a]pyridin-3-ylmethyl)-N-prop-2-ynyl-4-trifluoromethyl-<br>
benzamide<br><br><br>
To a solution of N-(6-methyl-2-p-tolyl-imidazo[1,2-<br>
a]pyridin-3-ylmethyl)-4-trifluoromethyl-benzamide (1<br>
eq) in dry DMF are added 1.2 eq of NaH (60%) under<br>
argon. The suspension is stirred for 10 min at room<br>
temperature. Then 1.1 eq of 3-bromo-propyne are added<br>
and the corresponding mixture is stirred for lh at room<br>
temperature. After this period, NaOH 0.5 N is added.<br>
The mixture is extracted with dichloromethane. The<br>
organic layer is dried under magnesium sulphate and the<br>
solvent is removed in vacuo to obtain 0.16 eq of N-(6-<br>
methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-N-<br>
prop-2-ynyl-4-trifluoromethyl-benzamide.<br>
MS (ES) m/z = 462 (MH+)<br>
HPLC = 84%<br>
The compound of example 42 was prepared according to<br>
this procedure starting from the corresponding N-<br>
dealkylated amide.<br>
Example 42: Cyclopropanecarboxylic acid (6-methyl-2-p-<br>
tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-prop-2-ynyl-<br>
amide<br><br><br>
Yield: 29%<br>
MS (ES) m/z = 358 (MH+)<br>
HPLC = 84.7%<br>
Example 43: C-(6-Methyl-2-p-tolyl-imidazo[1,2-<br>
a]pyridin-3-yl)-methylamine<br><br>
A solution of 3 g (13 mmol) of bromide of 6-methyl-2-p-<br>
tolyl-imidazo[1,2-a]pyridin-4-ium in 50 mL of acetic<br>
acid is added to a solution of 1 g (13 mmol) N-<br>
methanolacetamide in 50 mL of acetic acid. To the<br>
resulting solution are added slowly 5 g (54 mmol) of<br>
concentrated sulphuric acid. The crude is stirred at<br>
room temperature for 1.5 hours and after at reflux for<br>
2 hours. The reaction is allowed to cool, and 50 mL of<br>
water are added. The crude is basified with ammonia 25%<br>
and extracted with dichloromethane. The organic layer<br>
is dried, filtered off and the solvent is removed in<br>
vacuo, to obtain 3.86 g (13.2 mmol, yield: 97%) of the<br>
corresponding amide. This amide is dissolved in 150 mL<br>
of ethanol and 50 mL of concentrated hydrochloric acid<br>
are added. The mixture is heated at reflux for 30 min.<br><br>
The crude is neutralized and the solvent is removed.<br>
The residue is extracted with DCM-water, and the<br>
organic layer is dried, filtered off and evaporated, to<br>
obtain 3.2 g (12.8 mmol, 97%) of C-(6-Methyl-2-p-tolyl-<br>
imidazo[1,2-a]pyridin-3-yl)-methylamine as a white<br>
solid.<br>
MS (ES) m/z = 252 (MH+)<br>
HPLC = 90%<br>
Example 44: 1-(4-Dimethylamino-phenyl)-3-(6-methyl-2-p-<br>
tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-urea<br><br>
To a solution of 1 eq of C-(6-methyl-2-p-tolyl-<br>
imidazo[1,2-a]pyridin-3-yl)-methylamine in pyridine is<br>
added a solution of 1-(4-Dimethylamino-phenyl)-<br>
isocyanate (1 eq) in pyridine. The mixture is stirred<br>
at room temperature for 2 4 hours. The solvent is<br>
removed and water is added to the residue. The solid<br>
thus obtained is filtered off, washed with water and<br>
dried over calcium chloride to give 1-(4-Dimethylamino-<br>
phenyl) -3- (6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-<br>
ylmethyl)-urea.<br>
Yield: 27%<br><br>
1H NMR (400 MHz, DMSO-d6) : δ 8.78 (NH, 1H, s) , 8.45<br>
(NH, 1H, m) , 7.80-6.80 (Ar, 11H, m) , 4.76 (CH2, 2H, d,<br>
J= 5.6 Hz), 2.85 (Me2N, 6H, s) , 2.43 (Ph-Me, 3H, s) ,<br>
2.4 (Me, 3H, s).<br>
MS (ES) m/z = 414 (MH+)<br>
HPLC =94%<br>
The compounds of examples 45-4 9 were prepared according<br>
to this procedure starting from the corresponding<br>
isocyanates.<br>
Example 45: 1-Ethyl-3-(6-methyl-2-p-tolyl-imidazo[1,2-<br>
a] pyridin-3-ylmethyl)-urea<br><br>
Yield: 27%<br>
1H NMR (400 MHz, DMSO-d6) : δ 8.84-7.41 (Ar, 7H, m) ,<br>
6.78 (NH, 1H, m) , 6.08 (NH, 1H, m) , 4.67 (CH2, 2H, d,<br>
J= 5.2 Hz), 3.01 (CH2, 2H, quint, J= 6.8 Hz), 2.44 (Ph-<br>
Me, 3H, s), 2.4 (Me, 3H, s) , 0.97 (Me-CH2, 3H, t, J=<br>
6.8 Hz).<br>
MS (ES) m/z = 323 (MH+)<br>
HPLC = 100%<br>
Example 46: 1-Isopropyl-3-(6-methyl-2-p-tolyl-<br>
imidazo[1,2-a]pyridin-3-ylmethyl)-urea<br><br><br>
Yield: 28%<br>
1H NMR (400 MHz, DMSO-d6) : δ 8.83-7.42 (Ar, 7H, m) ,<br>
6.61 (NH, 1H, m) , 5.93 (NH, 1H, d, J= 8 Hz), 4.68 (CH2,<br>
2H, d, J= 5.2 Hz), 3.67 (CH-Me2, 1H, m) , 2.43 (Ph-Me,<br>
3H, s), 2.41 (Me, 3H, s) , 1.00 (Me2-CH, 6H, d, J= 6<br>
Hz) .<br>
MS (ES) m/z = 337 (MH+)<br>
HPLC = 100%<br>
Example 47: 1-Cyclopentyl-3-(6-methyl-2-p-tolyl-imidazo<br>
[1,2-a]pyridin-3-ylmethyl)-urea<br><br>
Yield: 36%<br>
1H NMR (400 MHz, DMSO-d6) : δ 8.79-7.40 (Ar, 7H, m),<br>
6.52 (NH, 1H, m) , 6.05 (NH, 1H, d, J= 7.6 Hz), 4.68<br>
(CH2, 2H, d, J= 5.2 Hz), 3.85 (CH, 1H, m), 2.42 (Ph-Me,<br>
3H, s), 2.4 (Me, 3H, s), 1.76-1.22 ((CH2)4, 8H, m) .<br>
MS (ES) m/z = 363 (MH+)<br>
HPLC = 99%<br><br>
Example 48: 1-Cyclohexyl-3-(6-methyl-2-p-tolyl-imidazo<br>
[1,2-a]pyridin-3-ylmethyl)-urea<br><br>
Yield: 46%<br>
1H NMR (400 MHz, DMSO-d6) : δ 8.75-7.40 (Ar, 7H, m) ,<br>
6.54 (NH, 1H, m) , 5.94 (NH, 1H, d, J= 6.8 Hz), 4.68<br>
(CH2, 2H, d, J= 5.2 Hz), 3.9 (CH, 1H, m) , 2.42 (Ph-Me,<br>
3H, s), 2.4 (Me, 3H, s), 1.72-1.04 ((CH2)5, 10H, m) .<br>
MS (ES) m/z = 377 (MH+)<br>
HPLC = 98%<br>
Example 49: 1-(6-Methyl-2-p-tolyl-imidazo[1,2-<br>
a]pyridin-3-ylmethyl)-3-phenyl-urea<br><br>
Yield: 30%<br>
1H NMR (400 MHz, DMSO-d6) : δ 8.43 (NH, 1H, s), 8.34-<br>
6.88 (Ar, 12H, m) , 6.83 (NH, 1H, t, J= 5.6 Hz), 4.74<br>
(CH2, 2H, d, J= 5.6 Hz), 2.35 (Ph-Me, 3H, s), 2.31 (Me,<br>
3H, s).<br><br>
MS (ES) m/z = 371 (MH+).<br>
HPLC =92%<br>
Example 50: (6-Methyl-2-p-tolyl-imidazo[1, 2-a]pyridin-<br>
3-ylmethyl)-carbamic acid p-tolyl ester<br><br>
To a solution of 1 eq of C-(6-Methyl-2-p-tolyl-<br>
imidazo[1,2-a]pyridin-3-yl)-methylamine in pyridine is<br>
added a solution of p-tolyl-chloroformiate (1 eq) in<br>
pyridine. The mixture is stirred at room temperature<br>
for 2 4 hours. The solvent is removed and water is added<br>
to the residue. The solid thus obtained is filtered<br>
off, washed with water and dried over calcium chloride<br>
to give (6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-<br>
ylmethyl)-carbamic acid p-tolyl ester.<br>
Yield: 16%<br>
1H NMR (400 MHz, DMSO-d6) : δ 8.41-6.93 (Ar, 11H, m) ,<br>
6.62 (NH, 1H, t, J= 5.6 Hz), 4.71 (CH2, 2H, d, J= 5.6<br>
Hz), 2.35 (impy-Ph-Me, 3H, s), 2.3 (Ph-Me, 3H, s), 2.28<br>
(Me, 3H, s).<br>
MS (ES) m/z = 386 (MH+)<br>
HPLC = 80%<br><br>
The compounds of examples 51-57 were prepared according<br>
to this procedure starting from the corresponding<br>
chloroformiates.<br>
Example 51: (6-Methyl-2-p-tolyl-imidazo[1,2-a]pyridin-<br>
3-ylmethyl)-carbamic acid prop-2-ynyl ester<br><br>
Yield: 5%<br>
1H NMR (400 MHz, DMSO-d6) : δ 8.21-7.15 (Ar, 7H, m) ,<br>
8.05 (NH, 1H, t, J= 5.2 Hz), 4.66 (CH2-C, 2H, d, J= 2.4<br>
Hz), 4.64 (CH2, 2H, d, J= 5.2 Hz), 3.5 (CH, 1H, t, J=<br>
2.4 Hz), 2.34 (Ph-Me, 3H, s), 2.31 (Me, 3H, s).<br>
MS (ES) m/z = 334 (MH+)<br>
HPLC = 98%<br>
Example 52: (6-Methyl-2-p-tolyl-imidazo[1,2-a]pyridin-<br>
3-ylmethyl)-carbamic acid methyl ester<br><br>
Yield: 30%<br><br>
1H NMR (400 MHz, DMSO-d6) : δ 8.23-7.14 (Ar, 7H, m) ,<br>
7.83 (NH, 1H, m) , 4.61 (CH2, 2H, d, J= 5.2 Hz), 3.56<br>
(MeO, 3H, s), 2.34 (Ph-Me, 3H, s) , 2.31 (Me, 3H, s).<br>
MS (ES) m/z = 310 (MH+)<br>
HPLC = 100%<br>
Example 53: (6-Methyl-2-p-tolyl-imidazo[1, 2-a]pyridin-<br>
3-ylmethyl)-carbamic acid benzyl ester<br><br>
Yield: 15%<br>
1H NMR (400 MHz, DMSO-d6) : δ 8.21-7.14 (Ar, 12H, m) ,<br>
7.98 (NH, 1H, m) , 5.08 (CH2-Ph, 2H, s) , 4.65 (CH2, 2H,<br>
d, J= 5.6 Hz), 2.34 (Ph-Me, 3H, s), 2.28 (Me, 3H, s).<br>
MS (ES) m/z = 386 (MH+)<br>
HPLC =86%<br>
Example 54: (6-Methyl-2-p-tolyl-imidazo[1,2-a]pyridin-<br>
3-ylmethyl)-carbamic acid 4-methoxy-phenyl ester<br><br><br>
Yield: 41%<br>
1H NMR (400 MHz, DMSO-d6) : δ 8.70-6.89 (Ar, 11H, m) ,<br>
8.50 (NH, 1H, m) , 4.74 (CH2, 2H, d, J= 5.2 Hz), 3.73<br>
(MeO, 3H, s), 2.45 (Ph-Me, 3H, s), 2.39 (Me, 3H, s).<br>
MS (ES) m/z = 402 (MH+)<br>
HPLC = 88%<br>
Example 55: (6-Methyl-2-p-tolyl-imidazo[1,2-a]pyridin-<br>
3-ylmethyl)-carbamic acid ethyl ester<br><br>
Yield: 23%<br>
1H NMR (400 MHz, DMSO-d6) : δ 8.46-7.32 (Ar, 7H, m) ,<br>
4.63 (CH2, 2H, d, J= 4.4 Hz), 4.02 (CH2-Me, 2H, m) ,<br>
2.49 (Ph-Me, 3H, s), 2.37 (Me, 3H, s) , 1.15 (Me, 3H, t,<br>
J= 6.8 Hz).<br>
MS (ES) m/z = 324 (MH+)<br>
HPLC = 81%<br>
Example 56: (6-Methyl-2-p-tolyl-imidazo[1,2-a]pyridin-<br>
3-ylmethyl)-carbamic acid phenyl ester<br><br><br>
Yield: 22%<br>
1H NMR (400 MHz, DMSO-d6) : δ 8.70-6.72 (Ar, 12H, m) ,<br>
8.56 (NH, 1H, m) , 4.76 (CH2, 2H, d, J= 5.6 Hz), 2.45<br>
(Ph-Me, 3H, s), 2.39 (Me, 3H, s).<br>
MS (ES) m/z = 372 (MH+)<br>
HPLC = 90%<br>
Example 57: (6-Methyl-2-p-tolyl-imidazo[1,2-a]pyridin-<br>
3-ylmethyl)-carbamic acid isopropyl ester<br><br>
Yield: 16%<br>
1H NMR (400 MHz, DMSO-d6) : δ 8.25-7.14 (Ar, 7H, m) ,<br>
7.75 (NH, 1H, d, J= 5.6 Hz), 4.81 (CH, 1H, m) , 4.62<br>
(CH2, 2H, d, J= 5.6 Hz), 2.34 (Ph-Me, 3H, s) , 2.31 (Me,<br>
3H, s), 1.17 (Me2CH, 6H, d, J= 6.4 Hz).<br>
MS (ES) m/z = 338 (MH+)<br>
HPLC = 98%<br>
The compounds of examples 58-90 were prepared according<br>
to the procedure described for example 44, starting<br>
from C-(6-Methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-yl)-<br>
methylamine and the corresponding acid chlorides.<br>
Example 58: Cyclobutanecarboxylic acid (6-methyl-2-p-<br>
tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-amide<br><br><br>
MS (ES) m/z = 334 (MH+)<br>
HPLC = 99%<br>
Example 59: Cyclopentanecarboxylic acid (6-methyl-2-p-<br>
tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-amide<br><br>
MS (ES) m/z = 348 (MH+)<br>
HPLC = 99%<br>
Example 60: Benzo[b]thiophene-3-carboxylic acid (6-<br>
methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-<br>
amide<br><br>
MS (ES) m/z = 413 (MH+)<br>
HPLC = 97%<br><br>
Example 61: 5-Methyl-pyrazine-2-carboxylic acid (6-<br>
methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-<br>
amide <br>
MS (ES) m/z = 372 (MH+)<br>
HPLC = 90%<br>
Example 62: 1-Methyl-1H-pyrrole-2-carboxylic acid (6-<br>
methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-<br>
amide <br>
MS (ES) m/z = 359 (MH+)<br>
HPLC = 90%<br>
Example 63: N-(6-Methyl-2-p-tolyl-imidazo[1,2-a]pyridin<br>
-3-ylmethyl)-nicotinamide<br><br>
MS (ES) m/z = 357 (MH+)<br>
HPLC =92%<br><br>
Example 64: 5-Chloro-4-methoxy-thiophene-3-carboxylic<br>
acid (6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-<br>
ylmethyl)-amide<br><br>
MS (ES) m/z = 427 (MH+)<br>
HPLC = 98%<br>
Example 65: 6-Oxo-1,4,5,6-tetrahydro-pyridazine-3-<br>
carboxylic acid (6-methyl-2-p-tolyl-imidazo[1,2-<br>
a]pyridin-3-ylmethyl)-amide<br><br>
MS (ES) m/z = 376 (MH+)<br>
HPLC = 99%<br>
Example 66: Benzo[c]isoxazole-3-carboxylic acid (6-<br>
methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-<br>
amide<br><br><br>
MS (ES) m/z = 397 (MH+)<br>
HPLC = 97%<br>
Example 67: 1,5-Dimethyl-1H-pyrazole-3-carboxylic acid<br>
(6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-<br>
amide<br><br>
MS (ES) m/z = 374 (MH+)<br>
HPLC = 99%<br>
Example 68: 1-Methyl-1H-indole-3-carboxylic acid (6-<br>
methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-<br>
amide<br><br><br>
MS (ES) m/z = 410 (MH+)<br>
HPLC = 98%<br>
Example 69: 2-Methyl-thiazole-4-carboxylic acid (6-<br>
methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-<br>
amide <br>
MS (ES) m/z = 377 (MH+)<br>
HPLC = 99%<br>
Example 70: [1,2,3]Thiadiazole-4-carboxylic acid (6-<br>
methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-<br>
amide<br><br>
MS (ES) m/z = 364 (MH+)<br>
HPLC = 99%<br>
Example 71: N-(6-Methyl-2-p-tolyl-imidazo[1,2-<br>
a]pyridin-3-ylmethyl)-2-thiophen-2-yl-acetamide<br><br><br>
MS (ES) m/z = 376 (MH+)<br>
HPLC = 98%<br>
Example 72: 5-Methyl-isoxazole-3-carboxylic acid (6-<br>
methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-<br>
amide <br>
MS (ES) m/z = 361 (MH+)<br>
HPLC = 97%<br>
Example 73: N-(6-Methyl-2-p-tolyl-imidazo[1,2-<br>
a]pyridin-3-ylmethyl)-6-(2,2,2-trifluoro-ethoxy)-<br>
nicotinamide<br><br>
MS (ES) m/z = 455 (MH+)<br>
HPLC = 91%<br><br>
Example 74: 1-Methyl-1H-imidazole-4-carboxylic acid (6-<br>
methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-<br>
amide <br>
MS (ES) m/z = 360 (MH+)<br>
HPLC = 99%<br>
Example 75: 6-Methoxy-2-oxo-2H-chromene-3-carboxylic<br>
acid (6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-<br>
ylmethyl)-amide<br><br>
MS (ES) m/z = 454 (MH+)<br>
HPLC = 89%<br>
Example 76: 4-Methoxy-thiophene-3-carboxylic acid (6-<br>
methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-<br>
amide <br><br>
MS (ES) m/z = 392 (MH+)<br>
HPLC = 93%<br>
Example 77: 5-Methoxy-thiophene-2-carboxylic acid (6-<br>
methyl-2-p-tolyl-imidazo [1, 2-a]pyridin-3-ylmethyl)-<br>
amide<br><br>
MS (ES) m/z = 392 (MH+)<br>
HPLC = 91%<br>
Example 78: 1-Methyl-1H-imidazole-2-carboxylic acid (6-<br>
methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-<br>
amide<br><br>
MS (ES) m/z = 360 (MH+)<br>
HPLC = 90%<br>
Example 79: 4-Methyl-[1,2,3]thiadiazole-5-carboxylic<br>
acid (6-methyl-2-p-tolyl-imidazo[1, 2-a]pyridin-3-<br>
ylmethyl)-amide<br><br><br>
MS (ES) m/z = 378 (MH+)<br>
HPLC = 91%<br>
Example 80: 3-Furan-2-yl-N-(6-methyl-2-p-tolyl-<br>
imidazo[1,2-a]pyridin-3-ylmethyl)-acrylamide<br><br>
MS (ES) m/z = 372 (MH+)<br>
HPLC = 96%<br>
Example 81: Thiazole-4-carboxylic acid (6-methyl-2-p-<br>
tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-amide<br><br>
MS (ES) m/z = 363 (MH+)<br>
HPLC = 98%<br><br>
Example 82: Thiophene-3-carboxylic acid (6-methyl-2-p-<br>
tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-amide<br><br>
MS (ES) m/z = 362 (MH+)<br>
HPLC = 95%<br>
Example 83: 2,5-Dimethyl-oxazole-4-carboxylic acid (6-<br>
methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-<br>
amide <br>
MS (ES) m/z = 375 (MH+)<br>
HPLC = 98%<br>
Example 84: 1-Cyclopropyl-2,5-dimethyl-1H-pyrrole-3-<br>
carboxylic acid (6-methyl-2-p-tolyl-imidazo[1,2-<br>
a]pyridin-3-ylmethyl)-amide<br><br><br>
MS (ES) m/z = 414 (MH+)<br>
HPLC = 95%<br>
Example 85: 4,5-Dichloro-isothiazole-3-carboxylic acid<br>
(6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-<br>
amide <br>
MS (ES) m/z = 432 (MH+)<br>
HPLC =92%<br>
Example 86: 1,2,5-Trimethyl-1H-pyrrole-3-carboxylic<br>
acid (6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-<br>
ylmethyl)-amide<br><br>
MS (ES) m/z = 387 (MH+)<br>
HPLC = 96%<br>
Example 87: 2,4-Dichloro-5-fluoro-N-(6-methyl-2-p-<br>
tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-benzamide<br><br><br>
MS (ES) m/z = 443 (MH+)<br>
HPLC = 91%<br>
Example 88: 5-Nitro-thiophene-3-carboxylic acid (6-<br>
methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-<br>
amide<br><br>
MS (ES) m/z = 407 (MH+)<br>
HPLC = 97%<br>
Example 89: Pyrazine-2-carboxylic acid (6-methyl-2-p-<br>
tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-amide<br><br>
MS (ES) m/z = 358 (MH+)<br>
HPLC = 97%<br><br>
Example 90: 3,5-Dimethyl-isoxazole-4-carboxylic acid<br>
(6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-<br>
amide<br><br>
MS (ES) m/z = 375 (MH+)<br>
HPLC = 93%<br>
The compounds of examples 91-100 were prepared<br>
according to the procedure described for example 22.<br>
Example 91: 2-Methyl-thiazole-4-carboxylic acid methyl-<br>
(6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-<br>
amide<br><br>
MS (ES) m/z = 392 (MH+)<br>
HPLC = 99%<br>
Example 92: 1,5-Dimethyl-1H-pyrazole-3-carboxylic acid<br>
methyl-(6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-<br>
ylmethyl)-amide<br><br><br>
MS (ES) m/z = 388 (MH+)<br>
HPLC = 90%<br>
Example	93: 1-Methyl-6-oxo-1,4,5,6-tetrahydro-<br>
pyridazine-3-carboxylic acid methyl-(6-methyl-2-p-<br>
tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-amide<br><br>
MS (ES) m/z = 404 (MH+)<br>
HPLC = 90%<br>
Example 94: Thiazole-4-carboxylic acid methyl-(6-<br>
methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-<br>
amide<br><br><br>
MS (ES) m/z = 377 (MH+)<br>
HPLC = 99%<br>
Example 95: 2,5-Dimethyl-oxazole-4-carboxylic acid<br>
methyl-{6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-<br>
ylmethyl)-amide<br><br>
MS (ES) m/z = 389 (MH+)<br>
HPLC = 91%<br>
Example 96: Pyrazine-2-carboxylic acid methyl-(6-<br>
methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-<br>
amide<br><br>
MS (ES) m/z = 372 (MH+)<br>
HPLC = 98%<br><br>
Example 97: 1-Methyl-1H-imidazole-4-carboxylic acid<br>
methyl-(6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-<br>
ylmethyl)-amide<br><br>
MS (ES) m/z = 374 (MH+)<br>
HPLC = 95%<br>
Example 98: 1-Methyl-1H-imidazole-2-carboxylic acid<br>
methyl-(6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-<br>
ylmethyl)-amide<br><br>
MS (ES) m/z = 374 (MH+)<br>
HPLC = 99%<br>
Example 99: 5-Methyl-isoxazole-4-carboxylic acid<br>
methyl-(6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-<br>
ylmethyl)-amide<br><br><br>
MS (ES) m/z = 375 (MH+)<br>
HPLC =99%<br>
Example 100: 5-Nitro-thiophene-3-carboxylic acid<br>
methyl-(6-methyl-2-p-tolyi-imidazo[1,2-a]pyridin-3-<br>
ylmethyl)-amide<br><br>
MS (ES) m/z = 421 (MH+)<br>
HPLC = 90%<br><br><br><br><br>
We claim :<br>
1, An imidazo[1,2-a] pyridine compound of formula (I):<br><br>
as well as pharmaceutically acceptable salts thereof;<br>
wherein<br>
R1 and R2 are independently selected from the group consisting of hydrogen, linear or branched alkyl(C1-C6), alkenyl<br>
(C2-C6), alkynyl(C2-C6), haloalkyl (C1-C6),-O-alkyl(C1-C6), fluoro, chioro and bromo;<br>
R3 is selected from the group consisting of hydrogen, linear orbranched alkyl (C1-C6), cycloalkyl (C3-C6), cycloalkyl<br>
(C3-C6) alkyl (C1-C6), alkenyl (C1-C6), alkynyl (C2-C6) alkyl (C1-C6), alkynyl (C2-C5), alkynyl (C2-C6) alkyl (C1-C6);<br>
R4 is selected from the group consisting of haioalkyl (C2-C6) cycloalkyl (C3-C5), cycloalkyl (C3-C6)alkyl(C1-C6),<br>
alkynyl (C2-C6) alkyl (C1-C6), alkyl(C1-C6)-O-alkyl (C1-C6), alkyl (C1-C6)-NH-alkyl (C1-C6), alkyl (C1-C6)-N(dialkyl<br>
(C1-C6)), -OR5, -NHR5,-NR5R6,<br><br>
phenylalkyl (C2-C6), Phenylalkenyl (C2-C6), naphthyl, monosubstituted naphthyl, disubstituted naphthyl, naphthy-<br>
lalkyl(C1-C6), naphthylalkenyl (C2-C6) furyl, substituted furyl, benzofuryl, substituted benzofuryl, pyrrolyl, substituted<br>
pyrrolyl, isoxazolyl, substituted isoxazolyl, benzoisoxazolyl, substituted benzoisoxazolyl, imidazolyl, substituted im-<br>
idazolyl, benzimidazolyl, substituted benzimidazolyl, indolyl, substituted indolyl, pyrazolyl, substituted pyrazolyl,<br>
thienyl, substituted thienyl, benzothienyl, substituted benzothienyl, thiazolyl, substituted thiazolyl, benzothiazolyl,<br>
substituted benzothiazolyl, quinolinyl, substituted quinolinyl, isoquinolinyl, substituted isoquinoiinyl, pyridyl, substi-<br>
tuted pyridyl, pyrazinyl, substituted pyrazinyl, 6-oxo-1,4,5,6-tetrahydropyridazinyl, substituted 6-oxo-1,4,5,6-tetrahy-<br>
dropyridazinyl, thiadiazolyl, substituted thiadiazolyl, isothiazolyl, substituted isothiazolyl, thienylmethyl, 2-oxo-<br>
chromenyl, substituted 2-oxochromenyl, 2-(furan-2-yl)vinyl; oxazolyl, substituted oxazolyl, and benzisoxazolyl;<br>
R5 and R6 are independently selected from the group consisting of hydrogen, linear or branched alkyl(C1-C6),<br>
phenylalkyl (C1-C6), haloalkyl (C1-C6), cycloalkyl (C3-C6), cycloalkyl(C3-C6)alkyl(C1-C6), alkenyl(C2-C6) and alky-<br>
nyl(C2-C6), alkenyl(C2-C5)alkyl(C1-C6), alkynyl(C2-C6)-alkyl(C1-C6), phenyl, substituted phenyl, heteroaryl, substi-<br>
tuted heteroaryl; and<br>
R7 and R8 are independently selected from the group consisting of linear or branched alkyl(C2-C6), cycloalkyl(C3-C6),<br>
alkenyl(C2-C6), alkynyl(C2-C6), -OH, - O-alkyl(C1-C6), -SH, -S-alkyl(C1-C6), halo-alkyl (C1-C6), ω,ω,ω-trifluoroalkyl<br>
(C1-C6), -NHalkyl(C1-C6), - Ndialkyl(C1-C6), -NO2, -CN, -SO2alkyl(C1-C6), - Coalkyl(C1-C6), -COOalkyl(C1-C6 ,<br>
-CO-NHalkyl(C1-C6), CONdialkyl (C1-C6), phenyl, substituted phenyl, heteroaryl, and substituted heteroaryl<br>
and wherein the substituents of the radicals that are substituted are selected from the group consisting of linear or<br>
branched alkyl (C2-C6), cycloalkyl (C3-C6), alkenyl(C2-C6), alkynyl (C2-C6), -OH, -O-alkyI (C1-C6), -SH, S-alkyl<br>
(C1-C5), halo-alkyl(C1-C6), ω,ω,ω-trifluoroalkyl (C1-C6), -NHalkyl(C2-C6), -Ndialkyl (C1-C6),-NO2, -CN, -SO2alkyl<br>
(C1-C6),-COalkyl(C1-C6),-COOalkyl(C1-C6),-CO-NHalkyl(C1-C6), -CONdialkyl(C1-C6), phenyl, substituted phenyl,<br>
heteroaryl, substituted heteroaryl, fluoro, chloro and bromo.<br><br>
2.	An imidazo [1,2-a] pyridine compound of formula (I):<br><br>
as well as pharmaceutically acceptable salts thereof;<br>
wherein<br>
R1 and R2 are independently selected from the group consisting of hydrogen, linear or branched alkyl (C1-C6),<br>
alkenyl (C2-C6), alkynyl (C2-C6), haloalkyl (C1-C6), -O-alkyl(C1-C6), fluoro, chloro and bromo;<br>
R3 is selected from the group consisting of hydrogen, linear or branched alkyl (C1-C6), cycloalkyl (C3-C6), cycloalkyl<br>
(C3-C6) alkyl (C1-C6), alkynyl (C2-C6), alkenyl(C2-C6)alkyl(C1-C6), alkynyl (C2-C6), alkynyl (C2-C6) alkyl (C1-C6);<br>
R4 is selected from the group consisting of haioalkyl(C2-C6), cycloalkyl (C3-C5), cycloalkyl (C3-C6) alkyl (C1-C6),<br>
alkynyl (C2-C6) alkyl (C1-C6), alkyl (C1-C6) - O-alkyl (C1-C6), alkyl (C1-C6) -NH-alkyl (C1-C6), alkyl (C1-C6)-N(dialkyl<br>
(C1-C6)), -OR5, -NHR5, -NR5R6,<br><br>
phenylalkyl (C2-C6), phenylalkenyl (C2-C6), naphthyl, monosubstituted naphthyl, disubstituted naphthyl, naphthyl-<br>
alkyl(C1-C6), naphthylalkenyl (C2-C6), furyl, substituted furyl, benzofuryl, substituted benzofuryt, pyrrolyl, substituted<br>
pyrrolyl, isoxazolyl, substituted isoxazolyl, benzoisoxazolyl, substituted benzoisoxazolyl, imidazolyl, substituted im-<br>
idazolyl, benzimldazolyl, substituted benzimidazolyl, indolyl, substituted indolyl, pyrazolyl, substituted pyrazolyl,<br>
thienyl substituted thienyl, benzothienyl, substituted benzothtenyl, thiazoiyl, substituted thiazolyl, benzothiszolyl,<br>
substituted benzothiazolyl, quinolinyl, substituted quolinyl, isoquinolinyl, substituted isoquinolinyl, pyridyl, and sub-<br>
stituted pyridyl;<br>
R5 and R6 are independently selected from the group consisting of hydrogen, linear or branched alkyl(C1-C6),<br>
phenylalkyl (C1-C6), haloalkyl (C1-C6), cycloalkyl (C3-C6), cycloalkyl (C3-C5) alkyl (C1-C6), alkenyl (C2-C6) and<br>
alkynyl (C2-C6), alkenyl(C2-C6) alkyl (C1-C6), alkynyl (C2-C6)alkyl(C1-C6), phenyl, substituted phenyl, heteroaryl,<br>
substituted heteroaryl; and<br>
R7 and R8 are independently selected from the group consisting of linear or branched alkyl(C2-C6), cycloalkyl(C3-C6),<br>
alkenyl(C2-C6),alkynyl(C2-C6), -OH,-O-alkyl(C1-C6),-SH, -S-alkyl (C1-C6), halo-alkyl (C1-C6), ω,ω,ω-trifluoroalkyl<br>
(C1-C6), -NHalkyl (C1-C6), - Ndialkyl (C1-C6), -NO2, -CN, -SO2alkyl (C1-C6), - COalkyl (C1-C6), -COOalkyl (C1-C6),<br>
-CO-NHalkyl(C1-C6). - CONdialkyl(C1-C6),- phenyl, substituted phenyl, heteroaryl and substituted heteroaryl.<br>
3.	A compound as claimed in claim 1, wherein R1 is a methyl group and R2 is a methyl group in para-position; and R3<br>
is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, i-propyl, cyclopropyl and 2-propynyl.<br>
4.	A compound as claimed in claim 3, wherein R4 is selected from the group consisting of cyclopropyl, cyclobutyl, 2-<br>
propynyl, N,N-dimethyl-4-aminophenyl, 2-furyl, 5-NO2-2-furyl, 2-pyrrolyl, 2-thienyl, 2-pyridyl, 4,6-difiuoro-2-pyridyl,<br>
2-chloro-4-pyridyl, 4-pyridyl, 5-methyl-2-pyrazinyl, 6-oxo-1,4,5,6-tetrahydro-pyridazin-3-yl, [1,2,3]thiadiazol-4-yI, 2-<br>
thienylmethyl, 1-methyl-1H-imidazol-2-yl, 4-thiazolyl, 2,5-dimethyl-4-oxazolyl and 3,5-dimethyl-4-isoxazolyl.<br><br>
5.	A compound as claimed in claim 4, wherein R4 is selected from the group consisting of cyclopropyl, 2-propynyl, N,<br>
N-dimethyl-4-aminophenyl, 2-furyl, 5-NO2-2-furyl, 2-pyrrolyl, 2-thienyl, 2-pyridyl, 4,6-difluoro-2-pyridyl, 2-chioro-4-<br>
pyridyf and 4-pyridyl.<br>
6.	A compound as claimed in claim 3, wherein R4 is -NR5R6.<br>
7.	A compound as claimed in claim 5, wherein R5 is hydrogen or methyl; and R6 is selected from the group consisting<br>
of methyl, ethyl, n-propyi, i-propyl, cyclopropyi, cyclopentyl, cyclohexyl, 2-propinyl and phenyl.<br>
6. A compound as claimed in claim 3, wherein R4 is -OR5.<br>
9. A compound as claimed in claim 8, wherein R5 is selected from the group consisting of methyl, ethyl, n-propyl, i-<br>
propyl, cyclopropyi, cyclopentyl, cyclohexyl, 2-propinyl, 4-methyl-phenyl, 4-methoxy-phenyl and phenyl.<br>
10.	A compound as claimed in claim 4, wherein said compound is selected from the group consisting of:<br>
Furan-2-carboxylic acid (6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-yImethyl)-amide;<br>
Pyridine-2-carboxylic acid (S-methyl-2-p-tolyl-imidazo[1,2-alpyridin-3-yimethyl)-amide;<br>
Thiophene-2-carboxylic acid (S-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-amide;<br>
Cyclopropanecarboxylic acid (6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-amide;<br>
5-Nitro-furan-2-carboxylic acid (S-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-amide;<br>
3,5-Difluoro-pyridine-2-carboxylic acid (6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-amide;<br>
6-Methoxy-benzothiazole-2-carboxylic acid (6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-amide;<br>
4-Dimethylamino-N-methyl-N-(6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-benzamide;<br>
cyclopropanecarboxylic acid methyl-(6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-amide;<br>
Pyridine-2-carboxylic acid methyl-(6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-amide;<br>
Thiophene-2-carboxylic acid methyl-(6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-amide;<br>
5-Nitro-furan-2-carboxylic acid methyl-(6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-amide;<br>
2-Chloro-N-methyl-N-(6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-isonicotinamide;<br>
Cyclobutanecarboxylic acid (6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-yimethyl)-amide;<br>
5-Methyl-pyrazine-2-carboxylic acid (6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-amide;<br>
6-Oxo-1,4,5,6-tetrahydro-pyridazine-3-carboxylic acid (8-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylme-<br>
thyl)-amide;<br>
[1,2,3]Thiadiazole-4-carboxylic acid (6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-amide:<br>
N-(6-yethyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-2-thiophen-2-yl-acetamide;<br>
1-methyl-1H-imidazole-2-carboxylic acid (6-methyl-2-p-tolyl-imidazo[1,2-alpyridin-3-ylmethyl)-amide;<br>
Thiazoie-4-carboxylic acid (16-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-amide;<br>
2,5-Dimethyl-Qxazole-4-carboxylic acid (6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-amide;<br>
3,5-Dimethyl-isoxazole-4-carboxylic acid (6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-amide; and<br>
Thiazole-4-carboxylic add methyl-(6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-amide.<br>
11.	A compound as claimed in claims 6 and 7, wherein said compound is selected from the group consisting of:<br>
1-(4-Dimethylamino-phenyl)-3-(6-methyl-2-p-tolyI-imidazo[1,2-a]pyridin-3-ylmethyl)-urea:<br>
1-Ethyl-3-(6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-urea:<br>
1-lsopropyl-3-(6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-urea:<br>
1-Cyclopentyl-3-(6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-urea:<br>
1-Cyclohexyl-3-(6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-urea; and<br>
1-(6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-3-phenyl-urea.<br><br>
12. A compound as claimed in claims 8 and 9, wherein said compound is selected from the group consisting of:<br>
(6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-carbamic acid p-tolyl ester;<br>
(6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-carbamic acid prop-2-ynyl ester;<br>
(6-Methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-carbamic acid methyl ester;<br>
(6-Methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-carbamic acid benzyl ester;<br>
(6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-yimefbyl)-carbamic acid 4-methoxy-phenyl ester;<br>
(6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-carbamic acid ethyl ester;<br>
(6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-carbamic acid phenyl ester, and<br>
(6-Methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-carbamic acid isopropyl ester.<br>
13.	A process for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof, as claimed in claim<br>
1, comprising reacting intermediate (II):<br><br>
with the nitrile of the formula R4-CN wherein R1, R2 and R4 are as defined in (I).<br>
14.	A process for preparing a compound of formula (I) or a pharmaceuticaliy acceptable saltthereof, as claimed in claim<br>
1, comprising reacting intermediate (III):<br><br>
with an acyl chloride of the formula R4-COCI, an isocyanate of the formula R4-CNO or a chloroformiate of the formula<br>
R4-OCOCI, wherein R1, R2 and R4 are as defined in (I).<br>
15. A process as claimed in claim 14, comprising reacting previously in the adequate acid conditions, an<br>
intermediate of formula (IV)<br><br><br>
with an intermediate of formula (V);<br>
CH3CONHCH2Q	(V)<br>
wherein Q is selected from the group consisting of -OH, -Oalkyl (C1-C3), -N+(alkyl(C1-C3)3Cl-, -N+(alkyl(C1-C3))<br>
38r-, -N+(alkyl(C1-C3)) 3I-, and then hydrolyzing the obtained intermediate (VI):<br><br>
to obtain said intermediate (Ill).<br>
16. A process as claimed in claim 15, comprising utilizing the intermediate of formula (V) wherein Q is -OH.<br>
17. A composition comprising a compound as claimed in claim 1 in association with a therapeutically inert carrier.<br>
18. A compound as claimed in claim 1 for preparing a medicament for treating or preventing diseases associated with<br>
GABAA receptor modulation.<br><br>
The present invention relates to novel imidazo[1,2- a]pyridine compounds<br>
of general formula (I) as well as pharmaceutically acceptable salts thereof;<br>
wherein R1, R2, R3 and R4 are as defined in the claims. The compounds have specific<br>
affinity for GABAA receptor and are therefore useful in the treatment and prevention<br>
of diseases modulated by α1- and α2-GABAA receptors.</nh></td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDE5ODAta29sbnAtMjAwNy1hYnN0cmFjdC5wZGY=" target="_blank" style="word-wrap:break-word;">01980-kolnp-2007-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDE5ODAta29sbnAtMjAwNy1hc3NpZ25tZW50LnBkZg==" target="_blank" style="word-wrap:break-word;">01980-kolnp-2007-assignment.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDE5ODAta29sbnAtMjAwNy1jbGFpbXMucGRm" target="_blank" style="word-wrap:break-word;">01980-kolnp-2007-claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDE5ODAta29sbnAtMjAwNy1jb3JyZXNwb25kZW5jZSBvdGhlcnMgMS4xLnBkZg==" target="_blank" style="word-wrap:break-word;">01980-kolnp-2007-correspondence others 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDE5ODAta29sbnAtMjAwNy1jb3JyZXNwb25kZW5jZSBvdGhlcnMucGRm" target="_blank" style="word-wrap:break-word;">01980-kolnp-2007-correspondence others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDE5ODAta29sbnAtMjAwNy1kZXNjcmlwdGlvbiBjb21wbGV0ZS5wZGY=" target="_blank" style="word-wrap:break-word;">01980-kolnp-2007-description complete.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDE5ODAta29sbnAtMjAwNy1mb3JtIDEucGRm" target="_blank" style="word-wrap:break-word;">01980-kolnp-2007-form 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDE5ODAta29sbnAtMjAwNy1mb3JtIDMucGRm" target="_blank" style="word-wrap:break-word;">01980-kolnp-2007-form 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDE5ODAta29sbnAtMjAwNy1mb3JtIDUucGRm" target="_blank" style="word-wrap:break-word;">01980-kolnp-2007-form 5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDE5ODAta29sbnAtMjAwNy1ncGEucGRm" target="_blank" style="word-wrap:break-word;">01980-kolnp-2007-gpa.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDE5ODAta29sbnAtMjAwNy1pbnRlcm5hdGlvbmFsIHB1YmxpY2F0aW9uLnBkZg==" target="_blank" style="word-wrap:break-word;">01980-kolnp-2007-international publication.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDE5ODAta29sbnAtMjAwNy1pbnRlcm5hdGlvbmFsIHNlYXJjaCByZXBvcnQucGRm" target="_blank" style="word-wrap:break-word;">01980-kolnp-2007-international search report.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDE5ODAta29sbnAtMjAwNy1wcmlvcml0eSBkb2N1bWVudC5wZGY=" target="_blank" style="word-wrap:break-word;">01980-kolnp-2007-priority document.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTk4MC1LT0xOUC0yMDA3LSgxMC0wMi0yMDEyKS1DT1JSRVNQT05ERU5DRS5wZGY=" target="_blank" style="word-wrap:break-word;">1980-KOLNP-2007-(10-02-2012)-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTk4MC1LT0xOUC0yMDA3LSgxMS0wMS0yMDEyKS1BQlNUUkFDVC5wZGY=" target="_blank" style="word-wrap:break-word;">1980-KOLNP-2007-(11-01-2012)-ABSTRACT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTk4MC1LT0xOUC0yMDA3LSgxMS0wMS0yMDEyKS1DT1JSRVNQT05ERU5DRS5wZGY=" target="_blank" style="word-wrap:break-word;">1980-KOLNP-2007-(11-01-2012)-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTk4MC1LT0xOUC0yMDA3LSgxMS0wMS0yMDEyKS1GT1JNLTEucGRm" target="_blank" style="word-wrap:break-word;">1980-KOLNP-2007-(11-01-2012)-FORM-1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTk4MC1LT0xOUC0yMDA3LSgxMS0wMS0yMDEyKS1GT1JNLTIucGRm" target="_blank" style="word-wrap:break-word;">1980-KOLNP-2007-(11-01-2012)-FORM-2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTk4MC1LT0xOUC0yMDA3LUFCU1RSQUNULTEuMS5wZGY=" target="_blank" style="word-wrap:break-word;">1980-KOLNP-2007-ABSTRACT-1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTk4MC1LT0xOUC0yMDA3LUFNQU5ERUQgQ0xBSU1TLnBkZg==" target="_blank" style="word-wrap:break-word;">1980-KOLNP-2007-AMANDED CLAIMS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTk4MC1LT0xOUC0yMDA3LUFTU0lHTk1FTlQucGRm" target="_blank" style="word-wrap:break-word;">1980-KOLNP-2007-ASSIGNMENT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTk4MC1LT0xOUC0yMDA3LUNPUlJFU1BPTkRFTkNFIDEuMS5wZGY=" target="_blank" style="word-wrap:break-word;">1980-KOLNP-2007-CORRESPONDENCE 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTk4MC1rb2xucC0yMDA3LUNPUlJFU1BPTkRFTkNFIE9USEVSUyAxLjIucGRm" target="_blank" style="word-wrap:break-word;">1980-kolnp-2007-CORRESPONDENCE OTHERS 1.2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTk4MC1LT0xOUC0yMDA3LUNPUlJFU1BPTkRFTkNFLTEuMy5wZGY=" target="_blank" style="word-wrap:break-word;">1980-KOLNP-2007-CORRESPONDENCE-1.3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTk4MC1LT0xOUC0yMDA3LUNPUlJFU1BPTkRFTkNFLnBkZg==" target="_blank" style="word-wrap:break-word;">1980-KOLNP-2007-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTk4MC1LT0xOUC0yMDA3LURFU0NSSVBUSU9OIChDT01QTEVURSktMS4xLnBkZg==" target="_blank" style="word-wrap:break-word;">1980-KOLNP-2007-DESCRIPTION (COMPLETE)-1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTk4MC1LT0xOUC0yMDA3LUVYQU1JTkFUSU9OIFJFUE9SVCBSRVBMWSBSRUNJRVZFRC5wZGY=" target="_blank" style="word-wrap:break-word;">1980-KOLNP-2007-EXAMINATION REPORT REPLY RECIEVED.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTk4MC1LT0xOUC0yMDA3LUVYQU1JTkFUSU9OIFJFUE9SVC5wZGY=" target="_blank" style="word-wrap:break-word;">1980-KOLNP-2007-EXAMINATION REPORT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTk4MC1LT0xOUC0yMDA3LUZPUk0gMS0xLjEucGRm" target="_blank" style="word-wrap:break-word;">1980-KOLNP-2007-FORM 1-1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTk4MC1LT0xOUC0yMDA3LUZPUk0gMTMgMS4xLnBkZg==" target="_blank" style="word-wrap:break-word;">1980-KOLNP-2007-FORM 13 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTk4MC1LT0xOUC0yMDA3LUZPUk0gMTMucGRm" target="_blank" style="word-wrap:break-word;">1980-KOLNP-2007-FORM 13.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTk4MC1LT0xOUC0yMDA3LUZPUk0gMTggMS4xLnBkZg==" target="_blank" style="word-wrap:break-word;">1980-KOLNP-2007-FORM 18 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTk4MC1LT0xOUC0yMDA3LUZPUk0gMi0xLjEucGRm" target="_blank" style="word-wrap:break-word;">1980-KOLNP-2007-FORM 2-1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTk4MC1LT0xOUC0yMDA3LUZPUk0gMi5wZGY=" target="_blank" style="word-wrap:break-word;">1980-KOLNP-2007-FORM 2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTk4MC1LT0xOUC0yMDA3LUZPUk0gMyAxLjIucGRm" target="_blank" style="word-wrap:break-word;">1980-KOLNP-2007-FORM 3 1.2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTk4MC1LT0xOUC0yMDA3LUZPUk0gMy0xLjEucGRm" target="_blank" style="word-wrap:break-word;">1980-KOLNP-2007-FORM 3-1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTk4MC1rb2xucC0yMDA3LUZPUk0gMy5wZGY=" target="_blank" style="word-wrap:break-word;">1980-kolnp-2007-FORM 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTk4MC1LT0xOUC0yMDA3LUZPUk0gNS5wZGY=" target="_blank" style="word-wrap:break-word;">1980-KOLNP-2007-FORM 5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTk4MC1rb2xucC0yMDA3LWZvcm0tMTgucGRm" target="_blank" style="word-wrap:break-word;">1980-kolnp-2007-form-18.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTk4MC1LT0xOUC0yMDA3LUdQQS5wZGY=" target="_blank" style="word-wrap:break-word;">1980-KOLNP-2007-GPA.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTk4MC1LT0xOUC0yMDA3LUdSQU5URUQtQUJTVFJBQ1QucGRm" target="_blank" style="word-wrap:break-word;">1980-KOLNP-2007-GRANTED-ABSTRACT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTk4MC1LT0xOUC0yMDA3LUdSQU5URUQtQ0xBSU1TLnBkZg==" target="_blank" style="word-wrap:break-word;">1980-KOLNP-2007-GRANTED-CLAIMS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTk4MC1LT0xOUC0yMDA3LUdSQU5URUQtREVTQ1JJUFRJT04gKENPTVBMRVRFKS5wZGY=" target="_blank" style="word-wrap:break-word;">1980-KOLNP-2007-GRANTED-DESCRIPTION (COMPLETE).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTk4MC1LT0xOUC0yMDA3LUdSQU5URUQtRk9STSAxLnBkZg==" target="_blank" style="word-wrap:break-word;">1980-KOLNP-2007-GRANTED-FORM 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTk4MC1LT0xOUC0yMDA3LUdSQU5URUQtRk9STSAyLnBkZg==" target="_blank" style="word-wrap:break-word;">1980-KOLNP-2007-GRANTED-FORM 2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTk4MC1LT0xOUC0yMDA3LUdSQU5URUQtU1BFQ0lGSUNBVElPTi5wZGY=" target="_blank" style="word-wrap:break-word;">1980-KOLNP-2007-GRANTED-SPECIFICATION.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTk4MC1LT0xOUC0yMDA3LU9USEVSUyAxLjEucGRm" target="_blank" style="word-wrap:break-word;">1980-KOLNP-2007-OTHERS 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTk4MC1LT0xOUC0yMDA3LU9USEVSUyBQQVRFTlQgRE9DVU1FTlRTLnBkZg==" target="_blank" style="word-wrap:break-word;">1980-KOLNP-2007-OTHERS PATENT DOCUMENTS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTk4MC1LT0xOUC0yMDA3LU9USEVSUy0xLjIucGRm" target="_blank" style="word-wrap:break-word;">1980-KOLNP-2007-OTHERS-1.2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTk4MC1LT0xOUC0yMDA3LU9USEVSUy5wZGY=" target="_blank" style="word-wrap:break-word;">1980-KOLNP-2007-OTHERS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTk4MC1LT0xOUC0yMDA3LVBFVElUSU9OIFVOREVSIFJVTEUgMTM3LnBkZg==" target="_blank" style="word-wrap:break-word;">1980-KOLNP-2007-PETITION UNDER RULE 137.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTk4MC1LT0xOUC0yMDA3LVJFUExZIFRPIEVYQU1JTkFUSU9OIFJFUE9SVC5wZGY=" target="_blank" style="word-wrap:break-word;">1980-KOLNP-2007-REPLY TO EXAMINATION REPORT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=YWJzdHJhY3QtMDE5ODAta29sbnAtMjAwNy5qcGc=" target="_blank" style="word-wrap:break-word;">abstract-01980-kolnp-2007.jpg</a></p>
		<br>
		<div class="pull-left">
			<a href="252350-rate-selection-for-eigensteering-in-a-mimo-communication-system.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="252352-a-process-for-production-of-gibberellic-acid-ga3-in-high-yield.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>252351</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>1980/KOLNP/2007</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>19/2012</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>11-May-2012</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>09-May-2012</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>01-Jun-2007</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>FERRER INTERNACIONAL S.A.</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>GRAN VIA CARLES III, 94 E-08028 BARCELONA</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>FALCO JOSE LUIS</td>
											<td>GRAN VIA CORTS CATALANES, 228, E-08004 BARCELONA</td>
										</tr>
										<tr>
											<td>2</td>
											<td>GUGLIETTA ANTONIO</td>
											<td>MAGDALENA CORCOLL, 16, E-08750 MOLINS DE REI</td>
										</tr>
										<tr>
											<td>3</td>
											<td>PALOMER ALBERT</td>
											<td>ALMERIA, 23, E-08014 BARCELONA</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>C07D 471/04</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/EP2005/055753</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2005-11-04</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>04105698.7</td>
									<td>2004-11-11</td>
								    <td>EUROPEAN UNION</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/252351-imidazo-1-2-a-pyridine-compounds-and-compositions by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 13:25:01 GMT -->
</html>
